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ABSTRACT 
Large-scale proteomic analyses of heterogeneous CNS preparations, such as 
isolated CNS synaptic vesicles, have provided a wealth of information related to synapse 
specific proteins and synaptic signaling pathways. However, these studies under-
represent, or lack entirely, many vesicle and neurotransmitter signaling pathways. In 
particular, the neuromodulatory adrenergic and cholinergic pathways are often under-
represented. In order to better understand the molecules and signaling pathways involved 
at cholinergic synapses, I have focused on the classic preparation of the electric lobe and 
electric organ of Torpedo californica. Many lines of evidence support the idea that in 
addition to acetylcholine, glutamate and ATP are also released from cholinergic 
synapses. Utilizing a single-vesicle imaging approach, I have found that individual 
synaptic vesicles from the electric ray possess neurotransmitter transporters for 
glutamate, ATP, and acetylcholine. These results help to explain neurotransmitter co-
release at cholinergic terminals. In addition to classic neurotransmitter, I have discovered 
that synaptic vesicles in the peripheral nervous system (PNS) and the central nervous 
system (CNS) possess small ribonucleic acids, including transfer RNA fragments and 
microRNAs. This discovery suggests that, in addition to releasing neurotransmitters that 
can induce local changes in postsynaptic membrane polarization, synaptic vesicles may 
also release small RNAs that can directly regulate local protein synthesis at the 
postsynaptic cell. 
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NOMENCLATURE 
SV Synaptic Vesicles 
ACh Acetylcholine 
VAChT Vesicular AcetylCholine Transporter 
VNUT Vesicular NUcleotide Transporter 
VMAT Vesicular MonoAmine Transporter 
VGLUT1, 2, 3 Vesicular Glutamate Transporter 1, 2, 3 
ATP  Adenosine Tri-Phosphate 
GABA   γ-Aminobutyric acid 
SLC     SoLute Carrier 
TIRF Total Internal Reflection Fluorescence 
5-HT   5-hydroxytryptamine 
NO Nitric Oxide  
sRNA small RiboNucleic Acid 
miRNA micro RiboNucleic Acid 
CNS  Central Nervous System 
PNS Peripheral Nervous System 
LTP Long Term Potentiation 
LTD              Long Term Depression 
trfRNA Transfer RNA Fragment 
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SNARE                          Soluble N-ethylmaleimide sensitive fusion protein Attachment 
Protein REceptor 
VIAAT                           Vesicular inhibitory amino acid transporter 
nAChR                           nicotinic AcetylCholine Receptor 
BDNF                            Brain-derived Neurotrophic Factor 
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1. INTRODUCTION
Synaptic transmission is the fundamental process through which neurons in the 
brain communicate with each other, and neurons in the spinal cord control the 
contraction of skeletal and smooth muscles and secretory glands in the periphery. This 
process occurs at specialized cell-to-cell adhesion sites termed synapses1. There are two 
types of synapses, electrical synapses and chemical synapses.   
Chemical synaptic transmission is the process by which neurotransmitter is 
released by a presynaptic neuron, in order to ultimately bind postsynaptic receptors on 
target cell membranes. Early observations of neurotransmitter release laid the foundation 
for the quantal hypothesis2. That is, neurotransmitter is released in discreet packets. The 
biophysical mechanism responsible for the quantal release of neurotransmitter remained 
undetermined until the discovery of vesicular organelles in the presynaptic terminal3,4. 
These vesicles, termed synaptic vesicles, are abundant in the presynaptic terminal of all 
chemical synapses. Some of these synaptic vesicles are docked on the presynaptic 
membrane, adjacent to a protein dense area called the Active Zone Material (AZM), just 
opposite to dense patches of receptors on the postsynaptic membrane. When an action 
potential arrives at the presynaptic terminal, exogenous calcium enters the terminal 
through electrically - gated calcium channels, and triggers the exocytosis of some of the 
docked synaptic vesicles. The process of exocytosis is calcium activated, but ultimately 
exocytosis is mediated by proteins in both the vesicle and presynaptic membranes. 
Protein conformational changes fuse the opposing membranes and release the vesicle’s 
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neurotransmitter. The fused vesicle’s membrane and proteins detach from the AZM, and 
are eventually recovered through a clathrin-mediated process termed endocytosis. 
Recycled synaptic vesicles can be reloaded with neurotransmitter for subsequent rounds 
of exocytosis5, a topic I will expand on in a subsequent section.       
Synaptic Vesicle Proteins 
            All synaptic vesicles are expected to share a core group of proteins, either 
integral to or associated with, the vesicle membrane. They are essential for vesicle 
trafficking to the active zone, vesicle exocytosis and endocytosis6. A brief list of the 
most important proteins, along with their proposed functional role in neurotransmission, 
can be found in Table 17,8. For example, synaptotagmin is a synaptic vesicle integral 
membrane protein and acts as the calcium sensor during calcium influx; the putative 
fusigenic SNARE core complex consists of cytosolic SNAP-25, presynaptic membrane 
anchored syntaxin and the synaptic vesicle integral protein synaptobrevin, and during 
endocytosis the cytoplasmic protein clathrin polymerizes to form a coat around the 
synaptic vesicle.  
          The vesicular neurotransmitter transporters are a group of synaptic vesicle proteins 
that are responsible for transporting neurotransmitter across the vesicle membrane, 
utilizing the electrochemical gradient provided by the VATPase in the vesicle membrane 
as a driving force9. The membrane transporters present in a synaptic vesicle, along with 
available cytosolic neurotransmitter (see Table 2), dictate the type of neurotransmitter 
loaded and released by a neuron. In this dissertation, I discuss 3 SoLute Carrier (SLC)  
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Official Name Other Name Transmembrane 
Domains 
Mass 
(kDa) 
Proposed Function 
Synaptotagmin P65 1 65 Ca2+ sensor: C2A and C2B domains 
bind Ca2+ 
SV2 Synaptic vesicle 
protein 2 
12 82-110 No clear function; possess many 
glycosylation sites. 
Synaptobrevin VAMP/V-SNARE 1 12 SV part of SNARE complex, 
important for synaptic vesicle 
fusion with presynaptic membrane 
Synaptophysin P38 4 38 No clear function; widely used as 
synaptic vesicle marker 
Rab Smg p25A / 25  Functions in vesicle sorting and 
trafficking 
NSF N-ethylmaleimide 
sensitive fusion 
proteins 
/ 76 ATPase required for SNARE 
complex recycling. 
Dynamin / / 100 Essential for vesicle formation in 
receptor-mediated endocytosis, 
vesicle recycling, caveolae 
internalization 
SNAP-25 Synaptosomal-
associated protein 
25 
/ 23 1 of 2 plasma membrane associated 
SNARE complex, involved in 
membrane fusion 
Syntaxin Q-SNARE/ T-
SNARE 
/ 38 1 of 2 plasma membrane associated 
SNARE complex, provides one 
helixs 
Clathrin / / 180/tri-
skeleton 
Forms a clathrin coat around a 
vesicle for endocytosis 
Synapsin I/IIa Protein I / 83 Tethers synaptic vesicles together, 
also links to cytoskeleton  
Complexin CPLX / 16 Proposed to inhibit spontaneous 
release at the stage of membrane 
fusion, promote synchronous 
release at the stage of membrane 
fusion 
α/β/γ - SNAP Alpha/ beta/gamma 
soluble NSF 
attachment protein 
/ 35 NSF adaptors to disassociate 
SNARE complex 
Munc - 18 Mammalian 
uncoordinated-18 
/ 68 Participates in the SNARE 
formation 
  
Table 1. Summary of proteins involved in synaptic vesicle exocytosis and 
endocytosis. (/ means not applicable) 
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Table 2. A summary of major neurotransmitters, neuromodulators and their 
receptors. 
Neurotransmitter types Examples Receptors Neuron 
types 
Amino acids Aspartate, glutamate, 
D-serine, GABA (γ-
Aminobutyric acid) and 
glycine 
NMDA (N-methyl-
D-aspartate 
receptor), AMPA 
(α-Amino-3-
hydroxy-5-methyl-
4-
isoxazolepropionic 
acid), GABAA and B
receptors 
Glutamatergic 
neurons, 
GABAergic 
neurons 
Monoamine Dopamine, 
norepinephrine, 
epinephrine, histamine 
and serotonin (5-
HydroxyTryptamine) 
Dopamine 
receptors, 
adrenergic 
receptors, 
histamine receptors 
and serotonin 
receptors 
Dopaminergic 
neurons, 
adrenergic 
neurons, 
noradrenergic 
neurons and 
serotonergic 
neurons 
Peptides Substance P, 
neuropeptide Y 
Neurokinin 
receptors, 
neuropeptide Y 
receptors 
Often found 
associated 
with 
serotonergic 
and 
noadrenergic 
neurons 
Gasotransmitters NO (Nitric Oxide) Soluble guanylyl 
cyclase 
/ 
Others ACh, ATP (Adenosine 
TriphosPhate) 
nAChR (nicotinic 
ACh Receptor), 
mAChR 
(muscarinic ACh 
Receptor) and 
purinergic 
receptors 
Cholinergic 
neurons, purinergi
c
neurons 
5 
families, known to transport neurotransmitters across the synaptic vesicle membrane. 
The three families are the SLC17, the SLC18, and the SLC32 families of proteins: 
1. SLC17 family members include the Vesicular Glutamate Transporters
(VGLUTs) 1, 2, 3. Three isoforms, VGLUT1, 2 and 3 transport glutamate into
the vesicle lumen10. VGLUT 1 is primarily expressed in glutamatergic neurons
residing in the cerebral cortex, the hippocampus and the cerebellar cortex11,
whereas VGLUT 2 is primarily expressed in glutamatergic neurons residing in
the thalamus, the brainstem and the deep cerebellar nuclei12. VGLUT 3 is not
necessarily expressed in glutamatergic neurons. It is often expressed in glial cells
and serotonergic, cholinergic and GABAergic neurons13. SLC17 family also
include the Vesicular Nucleotide Transporter (VNUT). VNUT transports ATP
into the vesicle lumen14. VNUT is primarily expressed in purinergic neurons in
the brain and adrenal gland14.
2. SLC18 family members include Vesicular MonoAmine Transporter (VMAT 1
and 2) and the Vesicular Acetylcholine Transporter (VAChT). VMAT 1 and 2
transport monoamine neurotransmitters including dopamine, serotonin,
norepinephrine, epinephrine and histamine into the vesicle lumen15. VAChT
transports acetylcholine (ACh) into vesicle lumen16. VMAT 1 is mainly
expressed in large dense-core vesicles of the Peripheral Nervous System (PNS),
as well as sympathetic neurons and blood platelets17, VMAT 2 is expressed in the
6 
Table 3. Summary of expression, ion coupling and synaptic phenotype by loss of 
function studies (Modified from Edwards Review31) 
Vesicular 
Transporter 
Family Location Ion Coupling Loss of function synaptic 
phenotype 
VGLUT1 SLC17 Glutamate 
neurons 
Glu- exchange 
nH+ 
Cl- dependent 
No glutamate release at 
certain synapses18,19 
VGLUT2 SLC17 Glutamate 
neurons 
Glu- exchange 
nH+ 
Cl- dependent 
No glutamate release at 
certain synapses20,21 
VGLUT3 SLC17 Non-
glutamate 
neurons 
Glu- exchange 
nH+ 
Cl- dependent 
ACh storage decrease in 
cholinergic synapse22 
VMAT2 SLC18 Monoamine 
neurons 
Amine+ 
exchange 2H+
(VMAT1)23,24 
Monoamine storage 
decrease, no release25-27 
VAChT SLC18 Cholinergic 
neurons 
ACh+ exchange 
2H+ 28 
Partial reduction: reduced 
ACh release29 
VGAT/VIAAT SLC32 Inhibitory 
neurons 
GABA/glycine 
exchange 
nH+ 
No release of GABA or 
glycine30 
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Central Nervous System (CNS) aminergic neurons, the sympathetic nervous 
system and mast cells15. VAChT is expressed in cholinergic neurons in both CNS 
and PNS32.  
3. SLC32 family members include the Vesicular Inhibitory Amino Acid 
Transporter (VIAAT), also named the Vesicular GABA Transporter (VGAT). 
VIAAT transports GABA, glycine and β-alanine into the vesicle lumen9. VIAAT 
is expressed in both GABAergic neurons and glycinergic neurons in the 
CNS30,33,34. 
Further information about vesicular transporter expression, ion coupling and synaptic 
phenotype in loss of function studies is provided in Table 3. 
Neurotransmitter Loading 
Dale’s principle states that neurons can be classified by the chemical 
neurotransmitter(s) they release from their nerve terminals35. In 1953, John Eccles 
proposed a simple and pragmatic interpretation of Dale’s principle, proposing that, to 
begin with, we assume that each neuron releases only one type of small molecule 
neurotransmitter at all of its synapses36. Based on this principle, chemical synapses have 
been identified based upon their sensitivity to pharmacological agents, their possession 
of the presynaptic molecular machinery to synthesize and load certain neurotransmitters, 
or the postsynaptic identification specific types of chemical receptors.  
          Many synapses appear to follow Dale’s principle; however, some neurons possess 
the enzymatic machinery necessary for the production of more than one neurotransmitter  
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and produce more than one type of neurotransmitter transporter. From a physiological 
perspective, the type of neurotransmitter stored and released at a terminal is determined 
by the enzymatic machinery and neurotransmitter transporter cofactors present in the 
presynaptic terminal, and ultimately the neurotransmitter transporters present on the 
synaptic vesicles. Thus one would expect that these terminals might release more than 
one neurotransmitter, and indeed, these neurons have been shown to co-release more 
than one type of neurotransmitter at their synaptic terminals37. The first observation of 
such a terminal was the PNS electric organ from Torpedo californica, where it was 
demonstrated that both ATP and ACh were loaded into synaptic vesicles and released 
from the terminals38,39,40. Additionally, synaptosomes isolated from the electric organs 
have been shown to co-release glutamate under stimulation41. In the CNS, there are 
many examples of neurons that possess multiple classes of neurotransmitter transporters, 
and a few well-controlled studies demonstrating the co-release of multiple types of 
neurotransmitter. Below is a table (Table 4) summarizing some examples of the 
neurotransmitter co-release in the CNS37. 
 To be classified as a neurotransmitter, small molecules must be loaded into 
synaptic vesicles and released from presynaptic terminals in a calcium dependent 
manner. In addition, the small molecules must bind ligand-activated receptors at or near 
the site of release. As stated in the previous paragraph, vertebrate NMJs release, in 
addition to ACh, ATP and glutamate. The evidence that ACh acts as a neurotransmitter 
at the vertebrate NMJ is substantial. The top surface of the postsynaptic endplate us 
densely populated by the nicotinic ACh receptors42,43. Released ACh binds to the 
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nicotinic ACh receptors at neuromuscular junction, which in turn open and help 
depolarize the muscle endplate, ultimately initiating the contraction of the muscle44-46. 
The evidence that ATP acts as a neurotransmitter at the NMJ is supported by the 
accumulation of the purinergic receptors P2X and P2Y at the endplate47. P2X receptors 
are expressed by neurons and Schwann cells48. Released ATP binds to the P2 receptors 
on Schwann cells P2 receptors and increase intracellular Ca2+ from either releasing the 
internal store or regulating Ca2+ entry49, and ultimately affects fast synaptic 
transmission50, modulating transmitter release. In addition, after ATP degraded to 
adenosine, adenosine can bind to P1 receptors on Schwann cells51. The evidence that 
glutamate acts as a neurotransmitter is localization of AMPA (α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid) and NMDA (N-Methyl-D-aspartic acid) receptors are 
receptors for glutamate on the muscle membrane52. In addition, excitatory amino acid 
transporters (EAATs), also known as glutamate transporters localize to the junctional 
folds of the endplate53. The application of glutamate to the endplate, triggers the release 
of nitric oxide, which has been shown to modulate the rate of synaptic vesicle 
endocytosis, the non-quantal release of ACh, and alter the probability of synaptic vesicle 
fusion54-56.  
          One important question that needs to be addressed in order to explain the many 
examples of multiple neurotransmitter transporters in the same neuron and/or the co-
release of multiple neurotransmitters at individual synaptic terminals is whether 
individual synaptic vesicles can possess multiple types of vesicle transporters. Two 
scenarios could explain the experimental observations of neurotransmitter co-release 
10 
(Figure 1) One, at a specific terminal, there is a heterogeneous population of synaptic 
vesicles, where each synaptic vesicle has only one type of neurotransmitter transporter, 
or two, there is homogeneous population of synaptic vesicles, where each synaptic 
vesicle has two or more kinds of neurotransmitter transporters. Some physiological 
experiments support the hypothesis that cholinergic vesicles possess at least two kinds of 
neurotransmitter transporters13, and therefore, should be capable of co-transmitter 
release. If synaptic vesicles cannot possess more than one type of transporter and 
transmitter, then a mechanism to regulate individual vesicle timing and release may be 
necessary to explain neurotransmitter co-release. 
As a step toward making direct tests of the hypothesis that synaptic vesicles 
contain multiple neurotransmitter transporters, I isolated synaptic vesicles from the 
cholinergic electric organ from the marine ray Torpedo californica. This is a classic 
cholinergic preparation like the neuromuscular junction, and it is an abundant source of 
cholinergic synaptic vesicles57. I utilized a single-molecule imaging approach based 
upon Total Internal Reflection Florescence Microscopy (TIRFM). TIRFM imaging is 
widely used in cell and molecular biology to observe cellular events happening on the 
surface of cells, including membrane receptor binding, endocytosis and exocytosis, actin 
myosin trafficking and so forth58. Conventional fluorescent microscope illuminates and 
excites fluorophores at multiple depths of the visual field of specimen, which results in 
high background of fluorescence and photobleaching of the fluorophores. TIRFM 
imaging makes use of an evanescent wave, and only illuminates the specimen adjacent  
11 
Co-release neurotransmitters Location 
GABA and ACh Starburst amacrine cells59 
GABA and glutamate GABAergic neurons at Medial nucleus 
of the trapezoid body during 
development co-release glutamate60; 
hippocampal mossy fiber glutamatergic 
synapse co-release GABA61 
ACh and glutamate Cholinergic neurons from medial 
hebenula nuclei62,63; lower motor 
neurons onto Renshaw cells64,65 
Monoamine and glutamate Ventral Tegmental Area and prefrontal 
cortex dopaminergic neurons66,67  
Table 4. Summary of known incidences of neurotransmitter co-release in the CNS. 
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Figure 1. Two proposed models of cholinergic synapse neurotransmitter 
transporter. A. Cholinergic synapse has heterogeneous population of synaptic vesicles; 
each has one type of neurotransmitter transporter. B. Cholinergic synapse has 
homogenous population of synaptic vesicles; each has at least four types of 
neurotransmitter transporters. 
A 
B 
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to the coverslip and specimen surface region, a depth of approximately 100 nm into the 
specimen. Synaptic vesicles isolated from electric organs of the electric ray are around 
70nm in diameter. In this case, synaptic vesicles from Torpedo californica preparation 
were examined under a glass coverslip. Only the surface, where single layer of 
fluorescently labeled synaptic vesicles in the solutions (1mg/ml protein content) is 
present, is illuminated. My evidence supporting the hypothesis that synaptic vesicles can 
contain multiple neurotransmitter transporters can be found in the second section of my 
thesis. 
Synaptic Vesicles Contain Small RNAs (sRNAs) 
The rate and timing at which neurotransmitter is released drives the post-synaptic 
activity at a synapse. That activity can have a profound effect on both the size and 
stability of a given synapse because it regulates not only the stability of proteins at the 
synapse that were synthesized within the cell body, but it also regulates the synthesis of 
proteins locally in the presynaptic and postsynaptic terminals. Current models strongly 
suggest that activity at the synapse regulates local protein synthesis68,69. In this model the 
release of neurotransmitter from the presynaptic terminal modulates postsynaptic levels 
of calcium, and via modulation of calcium levels indirectly controls local protein 
synthesis70. Changes in local protein synthesis then lead to changes in the post-synaptic 
structure such as receptor remodeling - either by synthesizing and stabilizing additional 
receptor proteins, or by the degradation of receptor proteins residing within the post 
synaptic membrane. This process is known as activity dependent synaptic plasticity, and 
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it is essential for dendritic outgrowth, synapse maturation, and synapse elimination 
during development and synaptic plasticity70.  
Protein translation is a complex process in which the information encoded in a 
messenger RNA (mRNA) sequence is used as a template in order to synthesize an 
amino-acid polypeptide chain, or protein71,72. Protein synthesis involves many types of 
macromolecules, including ribosomes, mRNAs, and transfer - RNAs (tRNAs)73. The 
translation process is tightly regulated by translation initiation factors, elongation 
factors, releasing factors and their regulators. Other factors regulating protein translation 
include the stability of individual mRNA transcripts and the rate at which translation 
occurs.  
Given the importance of local protein synthesis at the synapse, and its 
dependence on local activity, I hypothesized that synaptic vesicles might, in addition to 
neurotransmitter, contain small molecules that can directly regulate translation. One such 
class of small molecules includes short strands of non-coding ribonucleic acids (RNA; < 
50 nucleotides in length) that have been shown to have profound effects on transcription 
and translation. Short non-coding RNAs, or small RNAs (sRNAs) are a broad class of 
molecules that include RNA species such as micro-RNAs (miRNAs), small interfering 
RNAs (siRNAs), and transfer RNA fragments (trfRNAs).  The different classes of 
sRNAs can alter transcription and translation through distinct mechanisms74. For 
instance, sRNAs can, along with certain proteins, form a RNA-induced silencing 
complex (RISC).  These ribonucleoprotein complexes can cleave specific mRNA based 
upon the template provided by the sRNA. In addition, RISC complexes can also repress 
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protein translation by modulating the loading of ribosomes and by associating with other 
regulatory factors. sRNAs such as trfRNAs affect translation through alternative, non-
RISC pathways.  One such pathway is by binding directly to an elongation factor 
necessary for protein translation75.  
As a first step towards testing whether synaptic vesicles might store and release 
sRNAs in order to affect local protein synthesis, I tested and demonstrated that sRNAs 
are associated with synaptic vesicles. In addition to being associated with synaptic 
vesicles I also demonstrated that the vesicles protect the sRNAs from degradation by 
Ribonuclease (RNase).  In this dissertation, I discuss three sRNA families that I find 
associated with synaptic vesicles. The three families are the miRNAs, the trfRNAs, and 
the YRNAs: 
1. Mature miRNAs are around 21 nucleotides in length. The biogenesis of 
miRNA has been extensively studied for the last decade. Briefly, longer and 
intramolecular double strand RNA, also known as pri-miRNAs (primary 
miRNAs), are produced by a specialized ribonuclease III76 - in animals, pri-
miRNAs are cleaved by RNA polymerase III Drosha into pre-miRNAs 
(precursor miRNAs)77. A second RNase III, Dicer, cleaves pre-miRNAs into 
miRNA-miRNA duplexes. One miRNA strand is preferentially bound to the 
protein Argonaute (AGO), and loaded into an AGO-containing RNA-induced 
silencing complex (RISC)78 79, while the other strand gets degraded80. The 
miRNA in the RISC complex acts as a guide to target the RISC complex to 
specific mRNAs.  Once bound by a RISC complex, targeted mRNAs can 
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either be cleaved and degraded or target mRNA translation can be 
repressed81,82. Thus, miRNAs play important roles in posttranslational gene 
regulation by translational inhibition and mRNA destabilization. 
2. Mature trfRNAs range in size from 28-34 nt, and are approximately half the 
size of mature transfer-RNAs (tRNAs; 76-90 nt). The biogenesis of at least 
some trfRNAs begins with the cleavage of a mature tRNA near the anticodon 
loop by the RNase angiogenin83. Full length tRNAs have a well defined role 
in protein synthesis – they can be charged with specific amino acids in order 
to assist with translation, or interact with a series of proteins, including 
elongation factors and amnoactyl-tRNA ligases84. The functional roles of 
trfRNAs are not fully elucidated; however, some are induced under stress 
conditions, and may be involved in the assembly of stress granules. One class 
of trfRNA can inhibit protein translation in a eukaryotic translation Initiation 
Factor 2α (eIF2α) dependent manner, and promote an integrated stress 
response program75,83,85,86.   
3. Y RNAs are a group of small non-coding RNAs (83-122 nucleotides)87. They 
are found in cytoplasmic extracts (Y1, Y3, and Y4) and nuclear 
extracts(Y5)88. The biogenesis of Y RNAs is not well defined. Metazoan Y 
RNAs are transcribed by RNA polymerase III from distinct promoters, 
independent of the miRNA pathway89,90. Y RNAs are identified as the RNA 
component of soluble ribonucleoproteins (RNPs) termed Ro RNPs, which 
have been detected in the sera of patients suffering from systemic lupus 
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erythematosus (SLE), a systemic autoimmune disease (or autoimmune 
connective tissue disease) in which the body’s immune system mistakenly 
attacks healthy tissues87,91. The Y1 RNA is the RNA component of the Ro 
RNP complex, and is associated with the autoimmune antigen proteins Ro60 
and La92. The functional role of Y RNAs, or their fragments, is still not 
known. It has been hypothesized that the Y RNAs affect DNA replication, 
and/or are involved in the regulation of cellular stress response and 
proliferation87. 
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2. INDIVIDUAL SYNAPTIC VESICLES FROM THE ELECTROPLAQUE OF
TORPEDO CALIFORNA, A CLASSIC CHOLINERGIC SYNAPSE, ALSO 
CONTAIN TRANSPORTERS FOR GLUTAMATE AND ATP*   
Overview 
The type of neurotransmitter secreted by a neuron is a product of the vesicular 
transporters present on its synaptic vesicle membranes and the available transmitters in 
the local cytosolic environment where the synaptic vesicles reside.  Synaptic vesicles 
isolated from electroplaques of the marine ray, Torpedo californica, have served as 
model vesicles for cholinergic neurotransmission.   Many lines of evidence support the 
idea that in addition to acetylcholine, additional neurotransmitters and or 
neuromodulators are also released from cholinergic synapses. We identified the types of 
vesicular neurotransmitter transporters present at the electroplaque using immunoblot 
and immunofluoresence techniques with antibodies against the vesicle acetylcholine 
transporter (VAChT), the vesicular glutamate transporters (VGLUT 1, 2, and 3), and the 
vesicular nucleotide transporter (VNUT). We found that VAChT, VNUT, VGLUT 1 and 
2, but not 3 were present by immunoblot, and confirmed that the antibodies were 
specific to proteins of the axons and terminals of the electroplaque. We used a single 
vesicle imaging technique to determine whether these neurotransmitter transporters were  
*Reprinted with permission from ‘Individual synaptic vesicles from the electroplaque of
Torpedo californica, a classic cholinergic synapse, also contain transporters for 
glutamate and ATP’ by Huinan Li and Mark L. Harlow, 2014. Physiological Reports, 
Volume 2, e00206, 1-11, Copyright 2014 by Wiley Online Library. 
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present on the same or different populations of synaptic vesicles. We found that greater 
than 85% of vesicles that labeled for VAChT co - labeled with VGLUT 1 or VGLUT 2, 
and approximately 70% co-labeled with VNUT. Based upon confidence intervals, at 
least 52% of cholinergic vesicles isolated are likely to contain all four transporters. The 
presence of multiple types of neurotransmitter transporters - and potentially 
neurotransmitters – in individual synaptic vesicles raises fundamental questions about 
the role of co-transmitter release and neurotransmitter synergy at cholinergic synapses. 
Introduction 
Neurons are often classified by the small molecule neurotransmitters they release 
from synaptic vesicles along their axons and axon terminals.  The type of 
neurotransmitter loaded into a synaptic vesicle is a product of the neurotransmitter 
transporters present in a vesicles membrane, combined with the local concentration of 
neurotransmitter and availability of cofactors necessary for active transport. Thus at a 
cholinergic synapse, the presynaptic bouton will contain the precursors and enzyme 
machinery to produce acetylcholine (ACh), and the synaptic vesicles present will contain 
the vesicular acetylcholine transporter (VAChT)94.  
The simple idea that each neuron secretes only one type of neurotransmitter has 
been thrown into doubt with examples of cholinergic, GABAergic and noradrenergic 
neurons that appear to co-release glutamate37,63. However, whether this co-release 
involves packaging of multiple transmitters into single synaptic vesicles is less clear.  
This is an important issue because it impacts how one thinks about the communication 
occurring at the synapse. Synaptic vesicles isolated from electroplaques of the marine 
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ray, Torpedo californica, have previously been shown to contain the vesicular 
acetylcholine transporter, as well as load and release the neurotransmitters (ACh) and 
adenosine triphosphate (ATP)40. Thus, in the case of the electroplaque, ACh and ATP 
are either in the same synaptic vesicles, or two populations of vesicles reside in the 
terminals. Additionally it has been demonstrated that synaptosomes from electroplaque 
release glutamate41, in agreement with studies that show some cholinergic neurons 
within the central nervous system (CNS) synthesize one or more vesicular glutamate 
transporters (VGLUT 1,2,3) and release glutamate at their terminals22,64,95. Two non-
mutually exclusive possibilities could account for cases where co-release has been 
demonstrated.  Either these neurons have a heterogeneous population of two or more 
distinct types of vesicles containing different neurotransmitter transporters, or these 
neurons possess a homogenous population of synaptic vesicles that contain multiple 
types of neurotransmitter transporters. 
To address the question of whether at one type of synapse the synaptic vesicles 
are heterogeneous or homogenous we have chosen to use vesicles isolated from the 
electroplaques of T. californica.  The electroplaque is a classic preparation that provides 
an abundance of cholinergic synaptic vesicles from one class of motor neuron57. Two 
types of neurotransmitter are stored in and released from vesicles at these terminals -
acetylcholine and ATP. In addition to the neurotransmitter transporters for acetylcholine 
and ATP14, we tested for the presence of glutamate transporters VGLUT 1, 2 and 311,96-
99; which are co-expressed in other cholinergic neurons. Western blot analysis confirms 
the presence of four neurotransmitter transporters in the isolated vesicle preparation, 
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immunofluorescence labeling on cryostat tissue sections of electroplaques is consistent 
with the immunogenic epitopes of the four neurotransmitter transporters residing in the 
“cholinergic” axons and presynaptic terminals, and total internal reflection fluorescence 
(TIRF)100 experiments on single vesicles101 provide evidence that individual synaptic 
vesicles likely contain four types of neurotransmitter transporters.  Therefore we 
conclude that vesicles in the axon and axon terminals of the electroplaque are a 
homogenous population containing at least four types of neurotransmitter transporters 
and three different neurotransmitter/neuromodulators including acetylcholine, ATP and 
glutamate. 
Materials and Methods 
Reagents 
Mouse monoclonal antibodies to VGLUT1 (N28/9), VGLUT2 (N29/29), 
VGLUT3 (N34/34), as well as the mouse monoclonal antibody for VAChT (N6/38) 
were purchased from Antibodies Incorporated (UC Davis/NIH NeuroMab Facility; 
Davis, Ca). Additional antibodies included VNUT rabbit polyclonal (ABN110), 
synaptophysin rabbit polyclonal (MAB5258), Goat Anti-Rabbit HRP, and Goat anti-
muse HRP (Millipore; Billerica, MS), and VAChT rabbit polyclonal ab68986 (Abcam; 
Cambridge, England) Fluorescently tagged secondary antibodies included Pacific Blue 
Goat anti-mouse (P31582), Alexa 488 Goat anti-rabbit (A-11034), Alexa 488 Goat anti-
Mouse (A-10667) (Invitrogen/ Life Technologies; Carlsbad, CA). Alexa 594 α-
bungarotoxin (B-13423), and FM 4-64 (T-13320) were used to label AChR and vesicles, 
respectively (Invitrogen).  Pro-long gold anti-fade (P36934) was used to mount 
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specimens (Invitrogen). Blue/green calibration beads (100 nm) were from Zeiss (Carl 
Zeiss; Oberkochen, Germany). All other reagents were purchased from Sigma-Aldrich 
(St. Louis, MO) unless otherwise noted. 
 All figures were adjusted using Image J (NIH; Bethesda, MS).  Schematic 
drawings and figure layout and labeling were done with Adobe Illustrator and 
Photoshop. (Adobe Systems Inc.; San Jose, CA.) 
Isolation and enrichment of cholinergic vesicles 
Methods were adapted from Ohsawa102. A Spex Freezer Mill 6800 (Spex Sample 
Prep; Metuchen, NJ) was cooled to -180o C and ~25 g of frozen electric organ from 
Torpedo californica (Aquatic Research Consultants; San Pedro, CA), containing 
abundant stacks of electroplaque was ground with 25 g of frozen buffer pellets (320 mM 
Sucrose, 10 mM TRIS-Cl, pH 7.4). The resulting powder of buffer and electric organ 
was placed in a beaker and warmed to 4°C with 50 ml of buffer solution (320 mM 
Sucrose, 10 mM Tris-Cl, pH 7.4, 4°C). The resulting slurry (100 ml) was centrifuged at 
20,000 rpm for 10 minutes (Beckman Coulter JA-20 rotor - Avanti J25 centrifuge) 
(Beckman Coulter; Brea, CA).  The resulting supernatant was centrifuged at 34,000 rpm 
for 40 minutes (Beckman Coulter 70ti rotor - Optima X80 centrifuge). The supernatant 
from this last centrifugation was loaded onto an 8 ml 0.6 M/1.2 M sucrose step gradient 
(10 mM Tris-Cl, pH 7.4), then centrifuged at 48,000 rpm for 2 hours (Beckman Coulter 
70ti rotor - Optima X80 centrifuge).  The 4-5ml fluffy layer, enriched in vesicles, was 
collected.  A 2 ml sample of enriched vesicles was filtered using a 0.22 µm spin column 
(Spin-x, Corning; Corning, NY) to remove any large debris or clusters of vesicles.  The 
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resulting filtrate was injected into a Pharmacia LC500 plus FPLC, and run through a 25 
cm 4% agarose bead column (Bioscience Beads; West Warwick, RI).  The FPLC was 
eluted with a buffer solution (0.2 M NaCl, 10 mM HEPES, pH 7.4) at a flow rate of 1.0 
ml/min. The second major peak was collected, and the vesicles concentrated to a protein 
concentration of 1 mg/mL or 8 mg/ml (measured by Bradford Assay – Bio-Rad)(Bio-
Rad Laboratories, Inc.; Hercules, CA) using a Stirred Cell apparatus with a 100 kDa 
filter (PLHK02510, Millipore). 
Electron microscopy 
A 5µl sample of enriched synaptic vesicles (20 mg/ml as determined by Bradford 
assay) was pipetted onto a slot grid that had been treated by glow discharge. Excess 
sample was removed by filter paper, and the grid was briefly washed in deionized water, 
followed by 2 s staining with uranyl acetate (Ted Pella; Redding, CA), followed by 
another wash103. The slot grid was viewed with a JEOL 1200 JEOL Ltd., Akishima-Shi, 
TKY Japan) operated at 100 kV. Images collected at 30,000 X and 50,000 X 
magnifications on a bottom-mounted 3072 x 3072, slow scan, lens-coupled CCD camera 
SIA 15C (SIA; Dulith, GA). 
Immunoblotting 
Four micrograms of vesicle protein was diluted 1:1 with Laemmli buffer (Bio 
Rad). The samples were loaded onto a 4 –20% Mini-Protein TGX gel (Bio Rad) and 
resolved for 35 min at 200 V. Proteins were transferred to a PVDF membrane (Bio Rad) 
and probed with antibodies to synaptophysin, VAChT, VNUT, VGLUT 1,2, or 3. 
Antibody binding was detected with horseradish peroxidase-conjugated secondary 
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antibodies and ECL Prime (GE Healthcare; Fairfield, CT). Chemiluminescence was 
quantified using a Chemicdoc XRS+ imager (Bio Rad). 
Fluorescent immunohistochemical labeling of frozen sections of electroplaque and wide-
field fluorescence 
Sections (30 microns thick) of electroplaque were cut with a cryostat (Leica; 
Solms, Germany), collected on slides, and stored at -80°C until processed for labeling.  
For labeling, slides were removed from the freezer and dried within a vacuum desiccator 
(Savant – Thermo Fisher Scientific; Waltham, MA) for 5 minutes.  The slices were then 
fixed in 4% paraformaldehyde for 5 minutes, rinsed with phosphate buffer solution 
(PBS), and washed in 0.1 M glycine in PBS for 1 hour.  Slides were extracted in 0.5% 
Triton PBS for 15 minutes on ice, and rinsed 3X for 10 minute in PBS. The samples 
were then blocked in 3% bovine serum albumin (BSA) in PBS for 1 hour. Primary 
antibodies were diluted 1:250 in 3% BSA PBS and incubated overnight at 4OC.  After 
washing 3 X 15 minutes in 3% BSA 0.1% Tween-20 PBS, the secondary antibodies 
(Alexa 488 Goat anti-Mouse or Alexa 488 Goat anti-rabbit) were diluted 1:1000 in 3% 
BSA and a 1:1000 Alexa 594 α-bungarotoxin added and incubated for 2 hours.  The 
slides were washed 3 X 15 minutes in 3% BSA PBS, blotted, and mounted on a 
coverslip in Pro-long Gold for imaging. 
  Images of the electroplaque were acquired using a Leica (Nussloch, Germany) 
epifluorescence microscope and a 40X (NA, 1.0) oil immersion objective, a CoolSnap 
HQ integrating CCD camera (PhotoMetrics, Huntington Beach, CA), and IPLab3.5 
software (BioVision, Exton, PA) using a Macintosh computer (Apple Computer, 
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Cupertino, CA). Filter sets used were standard HQ sets (#41001 for Alexa 488, and 
#41002 for Alexa 594; Chroma Technology, Rockingham, VT).  
Fluorescent immunohistochemical labeling of isolated synaptic vesicles and TIRF 
imaging of single vesicles 
After a final pass through a 0.22 µm spin column (Spin-x, Corning; Corning, 
NY) to remove any vesicles that may have become clustered during the stirred cell 
concentration step, 100 µl of synaptic vesicles (1 mg/ml) were transferred into 300 µl 
PBS (pH 7.4), and labeled with two rounds of primary and secondary antibodies 
following the procedure 101. Briefly, the vesicles were incubated for 4 hours with 1 µg of 
primary mouse antibody, incubated for 30 min with 20 µl anti-mouse IgG beads, briefly 
centrifuged, and the vesicle containing supernatant was then incubated with 0.5 µg goat 
anti-mouse secondary antibody labeled with Pacific Blue for 4 hours.  The vesicles were 
then incubated with 1 µg primary rabbit antibody for 4 hours, incubated for 4 hour with 
0.5 µg goat-anti-rabbit secondary labeled with Alexa 488, and finally incubated with 20 
µl anti-goat IgG beads.  The beads were pelleted and the supernatant collected for 
imaging.  The pairings of primaries were the following: VAChT mouse monoclonal and 
VNUT polyclonal, VGLUT1 mouse monoclonal and VAChT rabbit polyclonal, and 
VGLUT2 mouse monoclonal and VAChT rabbit polyclonal. 
FM4-64 104 was added to the labeled vesicles (final concentration 1 µM), and the 
samples were incubated on a glass bottom culture dish (MatTek P35G-1.5-20-C; 
Ashland, MA) for 1 hour prior to imaging to allow vesicles to settle on the coverslip.  
Culture dishes with settled vesicles were placed on a Zeiss Axio Observer Z1 
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Microscope with TIRF slider, 100X TIRF objective (NA 1.45). Images were acquired 
using AxioVision (Carl Zeiss; Oberkochen, Germany). Three separate images for each 
field were taken using laser lines and filter cubes paired to eliminate fluorescent cross 
talk between the dyes: laser line 401 with filter cube 73 HE was used for Pacific Blue, 
laser line 488 with filter cube 38 HE was used for Alexa 488, and laser line 561 with 
filter cube 74 HE was used for FM 4-64. Images were collected with a Roper S/W 
PVCAM EMCCD camera and analyzed using ImageJ (NIH) software.  Suitable spots 
detected in the FM4-64 channel were marked.  The other channels were then quantified 
for label.   
Confidence intervals for the binomial proportion were calculated using two-sided 
Agresti-Coull confidence limits 105 providing a statistical means to combine paired 
labeling experiments that otherwise would have been impossible due to secondary 
antibody specificity and optical isolation of the three color channels used in the TIRF 
microscopy. 
Results 
Synaptic vesicle enrichment 
Synaptic vesicles were isolated from the electric organ of T. californica using 
standard vesicle isolation techniques.  In order to verify that the synaptic vesicles were 
uniform and structurally intact, a sample of the vesicles was concentrated to 20 mg/ml, 
negatively stained103 and viewed with an electron microscope (Figure 2A). In agreement  
 
  
 27 
Figure 2. Synaptic vesicles can be enriched from electroplaques of T. californica 
and shown to contain 4 neurotransmitter transporters. A) Electron micrograph 
image (30,000 magnification) of negatively stained vesicles isolated and enriched from 
electroplaque tissue. Sample contains abundant ~80 nm vesicles (some marked with 
single arrowheads) and occasional large clusters of vesicles and debris (double 
arrowheads). A insert) Higher magnification (50,000) negative stain image shows 
characteristic profile of membrane vesicles, Scale bar = 100 nm. B) Immunoblot of the 
38 kD protein synaptophysin demonstrates isolation and enrichment of synaptic vesicles 
during the isolation procedure.  Synaptophysin was seen in the tissue (T), and discarded 
pellets (P1, and P2), however during isolation the majority of vesicles are maintained in 
the much larger by volume supernatant (S1 and S2) until the final centrifugation.  In the 
final centrifugation the vesicles move through the supernatant (S3) and collect on the 
fluffy layer (FL).  The fluffy layer was collected, and the synaptic vesicles were further 
enriched by size exclusion chromatography (SV).  Purified vesicles were tested by 
immunoblot and found to be positive for the ~60 kD transporter proteins: VAChT, 
VNUT, VGLUT1, VGLUT2.  Extra bands are possibly due to differences in protein 
glycosylation. No signal was detected for the transporter protein VGLUT3. 
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with previous studies, the vesicles of T. californica are larger (80-120 nm)106 than 
vesicles found at neuromuscular synapses in T californica107, or at neuromuscular 
synapses at other vertebrates (45-60 nm)108. Although single vesicle profiles were the 
dominant structure seen, some larger clusters were also present, and perhaps a result of 
the concentration procedure (Figure 2A). 
Immunoblotting of neurotransmitter transporters 
The electric organ of T. californica is derived from muscle fibers during 
development, and like all electrocytes, is a non-contractile muscle organ innervated by 
cholinergic neurons from the electric lobe.  Fractions collected during the isolation 
procedure were immunoblotted for the synaptic vesicle protein synaptophysin to verify 
the isolation and enrichment procedure.  Each lane contained the same amount of protein 
by Bradford Assay, however pellet and supernatant volumes were not equal.  As the 
isolation procedure advanced, synaptophysin was maintained and ultimately enriched in 
the final steps (Figure 2B), providing further confirmation that the vesicular profiles 
seen by negative stain are from isolated synaptic vesicles109.   
Immunoblotting was used to determine whether each of five types of 
neurotransmitter transporters representative of three types of neurotransmitters were 
present in the synaptic vesicles. As expected, synaptic vesicles isolated from the electric 
organ possess the cholinergic transporter VAChT (Figure 2B).  In addition to 
acetylcholine, it has previously been demonstrated that ATP is loaded and released by 
synaptic vesicles isolated from the electric organ38.  We tested for the presence of the 
purinergic ATP transporter in the vesicle preparation, and found it labeled for VNUT 
30 
(Figure 2B).  In addition to testing for the transporters of known neurotransmitters at the 
electric organ, we probed for the three known glutamatergic transporters.  Previous 
studies have demonstrated glutamatergic transporter expression in cholinergic 
neurons22,64, and in some cases glutamatergic signaling95.  By immunoblot, VGLUT 1 
and 2, but not 3 was shown to be present in the synaptic vesicle preparation (Figure 2B; 
Figure 3).  
As a further verification of antibody specificity we labeled cryostat sections of 
the electric organ.  An electric organ, present on either side of the ray, is made up of 
pancake-like stacks of non-contractile, muscle derived, cells termed electroplaques 
(Figure 4A).  On the top surface of each electroplaque is a high concentration of 
nicotinic acetylcholine receptors.  Four large nerve bundles originate from the electric 
lobe, and axons from these nerves travel between the stacks of electroplaque cells before 
turning 90 degrees and innervating the entire surface of the electroplaque cell with 
presynaptic boutons. We found that VNUT, VGLUT 1 and 2, and VAChT labeled the 
axons (Figure 4B,C; E-G).  In addition, we found labeling for each of the transporters 
was present above the postsynaptic surface of the electroplaque (labeled with α-
Bungarotoxin) (Figure 4B,C; E-H). 
Single vesicle imaging with TIRF microscopy 
Very little is known about the molecular components residing within individual 
synaptic vesicles, and virtually no information exists about the molecular homogeneity 
of vesicles within a nerve terminal. Recently a single molecule technique based upon 
total-internal-reflection-fluorescence (TIRF) microscopy100 has been developed that  
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Figure 3. Immunoblot of purified vesicles from rat CNS and Torpedo californica electric 
organ.  Rat synaptic vesicles were isolated from rat brains purchased from Pel-Freez Biologicals 
(Rogers, AR) by the isolation procedure in the methods section.   Three lanes of Torpedo electric 
organ vesicles were loaded in decreasing concentrations (only two lanes of torpedo vesicles were 
blotted against VNUT).  The lanes are Tc1 = 4 mg, Tc2 = 2 mg, and Tc3 = 1 mg.  One blank 
lane separated the lane loaded with 2 mg of isolated rat vesicles.   For each blot, the approximate 
location of the 60 kD marker was marked. The following antibodies were tested: VAChT, 
VNUT, VGLUT1, VGLUT2, VGLUT3. All antibodies were positive against the vesicles 
isolated from rat brain. 
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Figure 4. Antibodies against VAChT, VNUT, VGLUT1 and VGLUT2 stain axons 
and presynaptic boutons residing within the electric organ.  A) Cartoon depicting the 
electric organ of T. californica (1 side of the paired organ shown) and its innervation by 
four electromotor nerves that project from the electric lobe of the central nervous system 
(green).  From the surface, the electroplaque cells of the electric lobe appear as a 
honeycomb.  Viewed from the side the electroplaque cells appear as large, pancake-like 
stacks.  Each individual electroplaque has a top surface covered in nicotinic-
acetylcholine receptors (red surface).  That surface is richly innervated with presynaptic 
boutons and axons.  Axons run in between the pancake stacks before entering the target 
electroplaque and forming synapses. The drawing to the far right in A illustrates the 
view shown in the remainder of the figure; however in the immunostains, the receptor 
rich surface of each electroplaque commonly runs at an angle to the central core 
containing only axons.   B-H) Labeling with each of the neurotransmitter transporter 
antibodies was done in conjunction with α-Bungarotoxin to mark the postsynaptic 
surface on the electroplaque cells. B) VAChT polyclonal antibody, and C) VNUT 
polyclonal antibody.  D) Application of a secondary antibody to tissue to which no 
primary polyclonal was applied.  E) VAChT monoclonal antibody, F) VGLUT1 
monoclonal antibody G) VGLUT2 monoclonal antibody, and H) secondary antibody in a 
control to which no primary monoclonal antibody was applied.  Axons and presynaptic 
labeling can be seen in B, C and E-G, but no appreciable label was detected in the 
controls (D and H). Scale bar = 5 microns. 
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allows for the quantification of protein copy numbers present on single vesicles110.  In 
the CNS, the smaller glutamatergic vesicles (35nm) were shown to possess four 
VGLUT1 transporters per vesicle110.  We chose to use this technique on vesicles isolated 
from the electric organ to address the question of whether single synaptic vesicles could 
have multiple classes of neurotransmitter transporters.  Because the terminal is 
cholinergic, we chose to test the three other transporters VNUT, VGLUT1, and 
VGLUT2 in a pair-wise labeling with the VAChT.  The vesicle isolation procedure was 
designed to minimize vesicle clusters and larger cellular debris (Figure 2A). In addition, 
the plating density was tittered to reduce the probability of two vesicles residing within a 
sub-diffraction limited spot. In order to verify that single vesicles were imaged, the 
lipophilic dye FM4-64104 was added for two additional checks.  For the first check, the 
resulting fluorescent spots (single vesicles) were checked to ensure they possessed a 
similar fluorescent profile as 100 nm fluorescent control beads (Figure 5A). For the 
second check, the fluorescence intensity of each spot was quantified in order to verify 
that each sub-diffraction limited spot did not contain multiple vesicles (Figure 5B).  
Although it was a rare event due to the titer density, we did occasionally find spots that 
had double or even triple the intensity expected for a single vesicle. Fluorescent profiles 
from the 4-64 channel that did not match the shape of a single molecule event (simple 
point spread function), or that possessed multiple quanta of lipid stain (as measured by 
fluorescence) were excluded from this study.  Sites of FM4-64 label that met the above 
criteria were then examined for the presence of secondary label in the two additional 
channels.  One channel was optimized for the secondary label (Goat anti-mouse) Pacific  
  
 34 
Figure 5. TIRF microscope images of vesicles labeled with FM4-64 were used to 
verify the size and intensity of the spots matched that of a single vesicle. A) 
Fluorescent images were collected from 51 fluorescent beads (100 nm diameter) and 
compared to 51 synaptic vesicles labeled with FM4-64 from each of the fluorescent 
pairings in this study.  Although the fluorescent beads are brighter, the beads and the 
vesicles possess similar sized diameters and point spread function widths. Scale bar = 1 
micron.  B) The fluorescence intensity of each putative vesicle was quantified in order to 
verify that each sub-diffraction limited spot did not contain multiple vesicles.  If two 
vesicles reside adjacent to one another they may still appear as single spot with a similar 
cross sectional width in the X-axis; however, the photon count in the FM4-64 channel 
would equal the sum of the two vesicles.  Cross sections along the X-axis were taken of 
four vesicles (marked a the site of the line labeled by a diamond, square, circle or 
triangle), The diamond and square spots contain twice the intensity of labeling as the 
circle and triangle spots in the image, and are thus likely to be two adjacent vesicles 
within the same sub-diffraction labeled spot. 
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Blue, and the other secondary channel was optimized for the secondary label (Goat anti-
rabbit) Alexa 488.  The types of possible outcomes are diagramed in Figure 6 A-H. 
Instances of FM4-64 label with no additional label in either of the other channels were 
not quantified. Instances of single channel label (Pacific Blue or Alexa 488), or instances 
of dual channel label (Pacific Blue and Alexa 488) were quantified, examples of which 
can be seen in Figure 6 I-K.  
 Statistical analysis of the VAChT labeled vesicles found a high degree of pairing 
in the second label channel, with a majority of the vesicles that labeled with VAChT also 
labeled with VNUT (69%), VGLUT1 (86%), or VGLUT2 (88%). Further statistical 
groupings can be quantified based on pairwise comparisons using Agresti Coull 
confidence limits105.  In addition to containing a VAChT, 59% of vesicles are likely to 
contain VNUT and VGLUT1, 61% of VAChT vesicles are likely to contain VNUT and 
VGLUT2, 75% of VAChT vesicles are likely to contain VGLUT1 and VGLUT2, and 
52% of the single VAChT vesicles are expected to contain VNUT, VGLUT1, and 
VGLUT2 (Figure 7). 
Discussion 
In this study we used single vesicle imaging to examine whether cholinergic 
synaptic vesicles possess additional types of neurotransmitter transporters.  As observed 
by electron tomography, cholinergic vesicles at the frog’s neuromuscular junction 
possess a stereotypic structure and arrangement of transmembrane molecules and appear 
homogenous111.   We found that cholinergic vesicles isolated from the electric organ of 
T. californica have at least four different neurotransmitter transporters.  In addition to the  
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Figure 6. TIRF microscope images of single synaptic vesicles. During TIRF illumination, the 
excitation beam travels off-axis through the microscope objective causing the beam’s incident 
angle at the coverslip to be too shallow to allow the beam to pass into the sample, thus leading to 
the total internal reflection of the beam back into the objective.  An evanescent field of 
illumination, approximately 100 nm in depth, is created at the surface of the coverslip, allowing 
for selective illumination of single molecules residing on the coverslip.  A diagram of expected 
observations could include singly label vesicles A, B or dually labeled vesicles C.  FM4-64 was 
used in order to control for three possible scenarios: D) Non-labeled vesicles or debris, E-G) 
fluorescent secondary on the coverslip not associated with any synaptic vesicles, or H) spots that 
contained brighter than standard labeling in the FM4-64 channel, as discussed in Fig 3B, and 
were thus unlikely to be single vesicle events. Example TIRF images of dual labeled, single 
vesicle events for I) VAChT and VNUT, J) VAChT and VGLUT1, and K) VAChT and 
VGLUT2. Scale bar = 1 micron. 
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cholinergic transporter VAChT, a purinergic transporter VNUT and two glutamatergic 
transporters VGLUT1 and VGLUT2 were shown to co-localize with VAChT to 
individual vesicles.   
 Until recently, the stimulated release of acetylcholine and ATP from the motor  
neurons of the electric lobe40 stood as one of the few exceptions to Eccels’36 
interpretation of Dale’s hypothesis35 - one neuron, one neurotransmitter. Not only are the 
two neurotransmitters released from the presynaptic terminals in a stimulation dependent 
manner, ensemble measurements of synaptic vesicles isolated from T. californica clearly 
demonstrate that both neurotransmitters actively load into the synaptic vesicles. 
Subsequent work has demonstrated that ATP acts on specific purinergic receptors at 
terminals112, and the transporter responsible for loading ATP into the vesicles, VNUT, 
has been cloned and characterized14.  However, prior to this study, whether individual 
synaptic vesicles contained both cholinergic and purinergic transporters was unknown. 
Using single vesicle imaging we demonstrate that at least 69% of the VAChT containing 
vesicles also possess VNUT, indicating that indeed individual vesicles do contain both 
cholinergic and purinergic transporters and are therefore most likely filled with and 
secrete both ACh and ATP simultaneously. 
 Glutamate is perhaps the most abundant neurotransmitter in the nervous system 
of vertebrates.  Based upon our initial transcriptome of the electric lobe we believe 
homologs for all three glutamate transporters are present in T. californica (data not 
shown).  However, neuromuscular junctions in vertebrates like T. californica utilize 
acetylcholine as their primary excitatory neurotransmitter.  Still, many of the conditions 
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for considering glutamate as a neurotransmitter, or at least a neuromodulator, at 
cholinergic motor neurons have been met. Glutamate plasma membrane transporters 
used to remove glutamate after release are present in muscle cells, and in fact 
concentrated in the folds of the neuromuscular junction just opposite the presynaptic 
release site53.  Glutamate has been shown to activate a nitric oxide signaling pathway in 
muscle cells113 that in turn modulates both the number of vesicles released 
presynaptically114 and the amount of acetylcholine released by non-quantal means 56.  
Glutamate release from the presynaptic terminal has not been demonstrated at the 
vertebrate neuromuscular junction, although glutamate release has been demonstrated 
from lower motor neurons onto Renshaw cells64, and from synaptosomes isolated from 
T. californica41. We find that at least 86% of the VAChT containing vesicles also 
possess VGLUT1, and 89% possess VGLUT2.  At this time we cannot exclude the 
possibility that VGLUT3 might be present in these vesicles, and that the antibody used 
in this study was not specific to the homolog in T. californica. While the synapses at 
electroplaque cells are not contractile, the possibility that a vesicular glutamate 
transporter may also be present at vertebrate neuromuscular junctions warrants further 
study.   
 The results presented in this paper show single synaptic vesicles that possess two 
or more neurotransmitter transporters – with at least 52% of vesicles possessing all four 
neurotransmitter transporters (Figure 7).  Assuming more than one type of 
neurotransmitter to be present in the terminal, fusion of one of these vesicles with the 
plasma membrane would produce co-release of two or more neurotransmitters.  In  
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Figure 7. Single synaptic vesicle observations of vesicular transporters (VNUT, 
VGLUT1, or VGLUT2) co-labeled with VAChT, and confidence intervals of 
statistically paired transporters calculated using two-sided Agresti - Coull 
confidence limits. 
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addition to the ability to load more than one neurotransmitter, the transporters, and the 
neurotransmitters themselves, may alter the proton gradient (ΔpH) and membrane 
potential ΔΨ across the vesicle membrane, and in fact may work in a synergistic manner 
37,63. Ensemble measurements of acetylcholine loading into isolated CNS cholinergic 
vesicles show a marked increase in the presence of glutamate 22.  Glutamate is known to 
increase the ΔpH across the vesicle membrane, and ΔpH is the most important driving 
force for VAChT activity.  With a negative charge at cytosolic pH, ATP would also 
provide an increase in ΔpH, although an exact measurement of that activity would be 
difficult given the requirement of ATP for the vesicular proton pump.  The presence of 
multiple types of neurotransmitter transporters, taken as a whole, provide a mechanism 
to explain co-transmitter release, and in the case of cholinergic vesicles, synergistic 
neurotransmitter loading effects.   
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3. SYNAPTIC VESICLES CONTAIN SMALL RIBONUCLEIC ACIDS (SRNAS) 
INCLUDING TRANSFER RNA FRAGMENTS (TRFRNAS) AND MICRORNAS 
(MIRNAS)*  
 
 
Overview 
Synaptic vesicles (SVs) are neuronal presynaptic organelles that load and release 
neurotransmitter at chemical synapses. In addition to classic neurotransmitters, we have 
found that synaptic vesicles isolated from the electric organ of Torpedo californica, a 
model cholinergic synapse, contain small ribonucleic acids (sRNAs), primarily the 5’ 
ends of transfer RNAs (tRNAs) termed tRNA fragments (trfRNAs). To test the 
evolutionary conservation of SV sRNAs we examined isolated SVs from the mouse 
central nervous system (CNS). We found abundant levels of sRNAs in mouse SVs, 
including trfRNAs and micro RNAs (miRNAs) known to be involved in transcriptional 
and translational regulation. This discovery suggests that, in addition to inducing 
changes in local dendritic excitability through the release of neurotransmitters, SVs may, 
through the release of specific trfRNAs and miRNAs, directly regulate local protein 
synthesis. We believe these findings have broad implications for the study of chemical 
synaptic transmission.  
*Reprinted with permission from ‘Synaptic vesicles contain small ribonucleic acids 
(sRNAs) including transfer RNA fragments (trfRNA) and microRNAs (miRNA)’ by 
Huinan Li, Cheng Wu, Rodolfo Aramayo, Matthew Sachs and Mark L. Harlow, 2015. 
Scientific Reports, Volume 5, 14918, 1-14, Copyright 2014 by MacMillan Publisher 
International Limited. 
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Introduction 
Multiple downstream events occur upon the activity-dependent release of 
neurotransmitter at chemical synapses. Most obviously, the presynaptic release of 
neurotransmitter leads to a stereotypic electrical change across a postsynaptic cell 
membrane. Thus at vertebrate neuromuscular junctions the release of acetylcholine leads 
to the activation of nicotinic acetylcholine receptors on the muscle membrane, 
membrane depolarization and subsequent muscle contraction115-117.  More dynamically, 
the presynaptic release of neurotransmitter coupled with coincident local postsynaptic 
membrane depolarization leads to a change in synaptic physiology that can persist for 
minutes, hours or days118. These long term changes have been best characterized at 
central nervous system (CNS) synapses, and can lead to long term potentiation (LTP) or 
depression (LTD) of the synaptic coupling between the two cells.  In the short-term 
(minutes) both LTP and LTD rely upon changes in calcium, but for these synaptic 
changes to be consolidated for the long-term (hours and days) requires, in addition to 
calcium influx, local protein synthesis119. 
Local protein synthesis at the synapse requires a host of mRNAs, translation 
factors, and ribosomes69,120-122. In addition, it is suspected that microRNA (miRNA) and 
other non-coding RNA (ncRNA) that include, but are not restricted to, endogenous small 
interfering RNA (esiRNA), piwi-interacting RNA (piRNA), antisense and long-ncRNA, 
play a key role in regulating translation123. Mechanistically, the release of 
neurotransmitter presynaptically has been thought to indirectly drive the selective 
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control of postsynaptic protein synthesis through activity-based modulation of 
calcium124. 
We hypothesized that the presynaptic terminal might play a more direct role in 
the regulation of postsynaptic transcription and translation. Previous studies have 
identified sRNAs that are associated with synaptosomes, as well as sRNAs that are 
released from and taken into synaptosomes and sRNAs that associate with SV 
fractions125,126. As a first step to test the hypothesis that the presynaptic terminal might 
play a more active role in local protein synthesis, we looked for the presence of, and 
ultimately sequenced, small molecule RNAs (sRNAs) that not only associate with 
synaptosomes and SVs, but localize within the SVs. We first chose SVs isolated from 
the electroplaques of Torpedo californica, a classic peripheral nervous system (PNS) 
preparation that provides an abundance of cholinergic synaptic vesicles from one class 
of motor neuron57. We treated the SVs with RNase to remove any exogenous 
cytoplasmic RNA from the preparation, and after RNA extraction, found an abundance 
of sRNAs protected from degradation. Sequencing of the sRNAs derived from affinity 
purified SVs revealed the presence of 5’ tRNA fragments, with a 5’-fragment of 
glutamyl-tRNA (tRNAGlu) sequence constituting the most abundant of the sequences. 
We verified by northern blot that the 5’ fragments were not a result of the RNase 
treatment of the vesicles, and that the fragments were protected from degradation in the 
absence of (but not the presence of) detergent.  In situ hybridization of the most 
abundant fragment sequence confirmed the presence of the fragment in the axons and 
presynaptic terminals of the electroplaque. We extended the results to SVs isolated from 
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the mouse CNS. As with the electroplaque, we found an abundance of sRNA species 
that were co-enriched with SVs and were resistant to RNase degradation. The 5’-
fragment of tRNAGlu that was most abundant in cholinergic T. californica SVs was the 
second most abundant species of sRNA found in SVs isolated from the mouse brain. 
Other species of sRNAs were found to be abundant in mouse CNS vesicles, including 
known miRNAs, and most abundantly, 5’ RNA fragments of the Ro ribonucleoprotein 
associated Y1 RNA (RNY1)127. Together these observations not only support the idea 
that sRNAs are present within SVs, they also suggest that these sRNAs play key roles 
regulating local protein synthesis at the synapse. 
Results 
Cholinergic vesicles isolated from the electric organ contain RNA 
We isolated synaptic vesicles from the electric organ of the Pacific ray T. 
californica in order to provide an abundant, homogenous preparation of cholinergic 
SVs57. We chose a freeze grinding method of isolation that has been shown by others to 
retain more of the SV neurotransmitter content while offering a similar SV enrichment 
(~20 fold; Table 5) as other isolation procedures128,129. In addition, we wanted to isolate 
SVs residing within classic synaptosomal boutons as well as those present at less 
structured synaptic varicosities. SVs were collected from the middle of the 0.6 M (1.07 
g/ml density) sucrose gradient layer, well above the 1.2 M (1.17 g/ml) sucrose layer used 
to isolate exosomes130,131 or detect exosome markers132,133. The size of the vesicles we 
isolated averaged ~80nm (Figure 8a), larger than SVs within the vertebrate CNS  
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RNA totals 
Electric organ SVs fish 1 
SV pH10 DM RNase pHDR 
SV starting material protein (mg) .75 .75 .75 .75 .75 
RNA recovered after treatment (ng) 8142 10092 8958 450 372 
Amount of RNA loaded into gel (ng) 
Fig 1c 452 560 498 375 310 
Average sample RNA (SV,pH10,DM) (ng) 9064 
After RNAse RNA (ng) 450 
Fraction RNA RNase resistant 0.05 
Electric organ SVs fish 2 
SV pH10 DM RNase pHDR 
SV starting material protein (mg) .81 .81 .81 .81 .81 
RNA recovered after treatment (ng) 4926 5598 5874 258 258 
Average sample RNA (SV,pH10,DM) (ng) 5466 
After RNAse RNA (ng) 258 
Fraction RNA RNase resistant 0.05 
Electric organ SVs fish 3 
SV pH10 DM RNase pHDR 
SV starting material protein (mg) .63 .63 .63 .63 .63 
RNA recovered after treatment (ng) 10284 10716 9492 372 486 
Amount of RNA loaded into gel (ng) 
Fig 2b 285 298 264 206 270 
Average sample RNA (SV,pH10,DM) (ng) 10164 
After RNAse RNA (ng) 372 
Fraction RNA RNase resistant 0.04 
Table 5. Quantification of RNA from Torpedo californica experiments.  
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Figure 8.  Cholinergic SVs from the electric organ of Torpedo californica contain 
RNA.  a) Electron micrograph of negatively stained SVs isolated and enriched from 
electroplaque tissue. Sample contains abundant ~80 nm vesicles (some marked with 
arrows). b) Western-blot analysis of the synaptic vesicles during purification.  The SV 
protein synaptophysin was used as a marker during the enrichment. The isolation 
procedure includes the collection of the original slurry (Sl), two centrifugation 
supernatants and pellets (S1, P1 and S2, P2), followed by a sucrose density gradient 
centrifugation and collection of the SV fluffy layer (FL).  Further purification using size 
exclusion chromatography yields the final, enriched sample of SVs (SV).  Purified 
vesicles were tested by immunoblot and found to be positive for the ~60 kD vesicle 
acetylcholine transporter (VAChT). c) Abundant sRNAs co-enrich with the synaptic 
vesicles (SV).  These sRNAs are stable under high pH (pH10), or in the presence of 
detergent (DM).  After addition of RNase much of the RNA is degraded; however an 
RNase resistant ~32 nt band persists (RNAse).  The RNAse resistant band of RNA can 
be degraded in the presence of high pH, detergent, and RNAse (pHDR). Bands of gel 
underlined (_) indicate a 20-fold reduction of sample loaded. d) TIRF microscope 
images of SVs reveals that single SVs contain RNA, as demonstrated by triple-labeling 
of the SVs with the steryl dye FM4-64, VAChT, and the RNA dye Syto12. Five 
representative vesicles shown from a total of 307.  Scale bar = 1 µm. 
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Figure 9. Western blot analysis of purified synaptic vesicles from the electric organ of Torpedo 
californica and Ponceau staining of synaptic vesicles isolated with Dynabeads. a) The ~60 kd 
Vesicular AcetylCholine Transporter (VAChT) is shown in three lanes.  Lane 1) 0.5 µg SV loaded 2) 1 µg 
SV loaded and 3) 2 µg of SV loaded.  Further verification of antibody with this preparation described in Li 
& Harlow, 201431. b) A protein gel containing three lanes of samples were transferred to a membrane and 
total protein was imaged with Panceau stain (G-Biosciences; St Louis, MO).  SV lane shows 5 µg of 
purified synaptic vesicles, VAChT Dynabeads lane shows resulting affinity purified synaptic vesicles 
isolated with VAChT conjugated dynabeads, and Dynabeads lane shows parallel experiment 
demonstrating dynabeads without antibody conjugated do not isolate SVs or other material. 
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(~40nm)103 or SVs found at vertebrate neuromuscular junctions (~50nm)107,108, but 
normal for vesicles from this preparation106.  As further verification that the isolated 
vesicles were neuronal in origin, we found by western blot analysis that the synaptic 
vesicle marker synaptophysin109 was enriched during isolation and that the vesicular 
acetylcholine transporter (VAChT)94 was present in the final preparation (Figure 8b; 
Figure 9).  We hypothesized that, in addition to neurotransmitter, SVs might contain 
RNA. To test this hypothesis we extracted RNA from the SV enriched preparation using 
a TRIzol extraction method and found abundant small molecule RNAs (Figure 8c). The 
cytoplasm of presynaptic terminals likely contains RNA molecules that might co-enrich 
with the SVs. In order to test whether the sRNAs were exogenous to or resided within 
the SVs we hypothesized that the vesicle membranes would provide protection from 
RNase degradation, thus allowing us to separate the cytoplasmic associated RNA from 
any vesicular protected RNA. We tested the preparation under five conditions.  In the 
presence of high pH buffer (pH 10 – known to disrupt RNA secondary and tertiary 
structure134) we observed no difference between the RNA isolated from the pH 7.4 SV 
preparations and the RNA isolated from the pH 10 SV preparation. We next chose, along 
with high pH, to add membrane detergent (DM; n-Decyl-β-D-Maltopyranoside) to 
disrupt the SV membranes without denaturing proteins135. Once again in the presence of 
pH 10 and DM we found no difference between the RNA we isolated from the untreated 
SV preparation.  Next we added RNase to the SVs. In the presence of RNase we found a 
substantial (~20 fold; Supplemental table 1) reduction in RNA, suggesting that 
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exogenous RNA does co-enrich with SVs. After RNase treatment a specific band of 
sRNAs of approximately ~32 nucleotide (nt) persisted. It was only when we combined 
pH 10, DM, and RNAse that we observed degradation of the ~32nt band (Figure 8c). 
 We have previously used a single vesicle imaging approach to study the co-
localization of multiple types of vesicular transporters to single vesicles in the 
cholinergic SV preparation110,136. As an initial step to verify that the sRNAs not 
degraded by RNase resided within cholinergic synaptic vesicles, and were not the result 
of RNA co-enriching with the SVs during the isolation procedure, we triple labeled 
isolated SVs in the presence of RNase (Figure 8d). Isolated SVs were labeled by 
immunofluorescence with a polyclonal antibody against VAChT, the nucleic acid dye 
SYTO12, and the membrane steryl dye FM4-64.  Because SVs are smaller than the 
diffraction limit, cholinergic vesicles were identified as small diffraction-limited dots 
visible in the FM4-64 channel that co-labeled for VAChT. Almost all cholinergic SVs 
co-labeled for RNA (96.1%; N=307) 
Cholinergic vesicles isolated from the electric organ contain tRNA fragments 
We sequenced the RNase resistant cholinergic SV’s sRNA. As a further step 
beyond size and density based purification methods, magnetic beads with conjugated 
antibodies against VAChT were used in the purification procedure (Supplemental Fig. 
1)131,137. SV non-luminal RNA was removed by treatment with RNase before luminal 
RNA was extracted by TRIzol. Five primary sequences with slight variations of length 
dominated the next generation sequencing reads, accounting for 60% of the total reads 
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(Table 6).  The most abundant primary sequence was that of a 5’ fragment of a tRNAGlu 
with the anticodon CUC (tRNAGluCUC) that is conserved across vertebrates (Figure 10a) 
  
  Sequence NT Copy #   Identity   
1 
UCCCUGGUGGUCUAGUGGUUAGGAUUCGG
CGC 32 2988724  5’-trfRNAGlu 
  
UCCCUGGUGGUCUAGUGGUUAGGAUUCGG
CGCUC 34 475743    
  
UCCCUGGUGGUCUAGUGGUUAGGAUUCGG
CGCU 33 402173    
  
UCCCUGGUGGUCUAGUGGUUAGGAUUCGG
CG 31 249273    
  
UCCCUGGUGGUCUAGUGGUUAGGAUUCGG
C 30 80234    
    4196147    
          
2 
GCAUUGGUGGUUCAGUGGUAGAAUUCUCG
CC 31 829169  5’-trfRNAGly  
  
GCAUUGGUGGUUCAGUGGUAGAAUUCUCG
CCU 32 412080    
  
GCAUUGGUGGUUCAGUGGUAGAAUUCUCG
CCUG 33 299964    
  
GCAUUGGUGGUUCAGUGGUAGAAUUCUCG
CCUGC 34 205669    
  
GCAUUGGUGGUUCAGUGGUAGAAUUCUCG
C 30 172506    
    1919388    
       
3 
GCAUCGGUGGUUCAGUGGUAGAAUUCUCG
CC 31 200366  5’-trfRNAGly 
  
GCAUCGGUGGUUCAGUGGUAGAAUUCUCG
CCUGC 34 115460    
  
GCAUCGGUGGUUCAGUGGUAGAAUUCUCG
CCUG 33 79351    
    395177    
       
4 
GUUUCCGUAGUGUAGUGGUUAUCACGUUC
GCC 32 219845  5’-trfRNAVal  
        
5 
GCCCGGAUAGCUCAGUCGGUAGAGCAUCA
GAC 32 130889  5’-trfRNALys  
       
       
Table 6. sRNAs identified through next-generation sequencing of affinity purified 
SVs from the electroplaque of T. californica
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Figure 10. Cholinergic vesicles isolated from the electric organ of T. californica 
contain 5’-tRNA fragments. a) Next-generation sequencing of RNA isolated from 
RNAse treated SVs enriched and affinity purified against VAChT reveals that 
cholinergic SVs contain 5’ fragments of tRNA. The most abundant fragment (5’-
trfRNAGlu) shown in red mapped onto the complete tRNA glutamate (tRNAGluCUC) 
shown in black. b) Northern analysis of RNA isolated from SVs verifies that the 5’-
trfRNAGlu sequence was not a product of RNase treatment. RNA isolated from SVs 
purely isolated (SV), at pH10 (pH10), in detergent (DM), treated with RNase (RNase), 
and treated simultaneously with pH10, detergent, and RNase (pHDR). Bands of gel 
underlined (_) indicate a 20-fold reduction of sample loaded. c) Northern analysis of 
total RNA (Trizol) and tRNA enriched RNA (LiCl) isolated from the electric lobe (LB) 
and electric organ (OG) of T. californica reveals full length tRNAGluCUC and 5’-
trfRNAGlu were found in near equal abundance in the electric organ, whereas 5’-
trfRNAGlu was more abundant than tRNAGluCUC in the electric lobe.  
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followed by 5’ fragments of two different tRNAs specifying glycine (tRNAGlyCCC), a 5’ 
fragment of tRNA Valine (5’-trfRNAValCAC), and a 5’ fragment of tRNA Lysine 
(trfRNALysUUU). Fragments of tRNA, both 5’ and 3’, are signaling molecules cleaved by 
the vertebrate RNase angiogenin86,138,139, and are designated 5’- and 3’- trfRNAs (for 
stress-induced tRNA fragment). We verified that the 5’-trfRNAs were not a result of the 
RNase treatment used in the isolation procedure by northern analysis of the most 
abundant 5’-trfRNAGlu sequence (Figure 10b; Figure 11; Table 7). The northerns were 
conducted three times, each with RNA isolated from SVs prepared from separate fish. 
Only a ~32nt band was observed in samples of the isolated SVs, pH 10 treated SVs, 
membrane detergent (DM) treated SVs, and RNase treated SVs. RNAs from the SV 
sample treated with pH 10-DM-RNase were degraded, providing further evidence that 
the 5’-trfRNAs reside within the cholinergic SVs, and are not a product of the RNAse 
treatment (Figure 8b). 
 To test whether the full-length tRNAGluCUC could be found in the presynaptic 
electric lobe and/or the postsynaptic electric organ we extracted total RNA from the two 
tissues for northern anaylsis.  Full-length tRNAGluCUC and 5’-trfRNAGlu were found in 
near equal abundance in the electric organ, whereas 5’-trfRNAGlu was more abundant 
than tRNAGluCUC in the electric lobe (Figure 10c; Figure 11; Table 7). We further 
enriched for tRNA from total RNA preparations using sodium acetate and LiCl 
extraction140, and observed a similar pattern of tRNAGluCUC and 5’-trfRNAGlu abundance 
in the tissues (Figure 10c; Figure 11; Table 7).   
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Figure 11. (b and c) Northern quantification based upon comparison to positive 
control and quantified using Imagequant. 
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Table 7.  Calculations of 5’-trfRNAGlu found in the SV preparation shown in Figure 
11b and 11c. Calculation of full-length tRNAGluCUC and 5’-trfRNAGlu found in the 
electric lobe and organ of T. californica shown in Fig. 11c.  TRIzol = total RNA 
preparation; LiCl = tRNA enriched preparation. First two lanes of LB and OG from each 
extraction method loaded with 80% sample (indicated by LB and OG); adjacent lanes of 
LB and OG loaded with 20% sample (4-fold dilution). 
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11b supplemental 
SV pH10 DM RNase pHDR 
Total RNA (ng) from preparation 10266 10716 9492 372 486 
Amount of RNA (ng) loaded in Fig 11b lane 285 298 264 206 270 
Northern Analysis - Calculation of 5’-
trfRNAGlu 
Amount of trfRNA in Northern (ng) 13 17 17 14 3 
Calculated amount of trfRNA from 
preparation (ng) 468 612 612 25 5 
Average sample ttl trfRNA (SV,pH10,DM) 
(ng) 564 
After RNAse (ng) 25 
Fraction of 5’-trfRNAGlu RNAse resistant 0.04 
11c supplemental – total RNA and LiCl sRNA enrichments from three T. californica rays. 
0.1 gram of tissue used from each organ Trizol LiCl 
Lobe (ng) Organ (ng) Lobe (ng) Organ (ng) 
Fish 1 Tissue 4872 1632 4987 4685 
Fish 2 Tissue 4416 1957 5362 3343 
Fish 3 Tissue 4459 1964 5388 3527 
total 13747 5553 15737 11555 
TRIzol LiCl 
LB OG LB OG LB OG LB OG 
Sample total and 
loaded RNA (ng) in 
Fig 11c lane 10998 4443 2749 1111 12590 9244 3147 2311 
TRIzol LiCl 
Northern Analysis LB OG LB OG LB OG LB OG 
Calculated amount of 
tRNA in Northern (ng) 0 4 0 0 0 2 0 0 
Calculated amount of 
trfRNA in Northern 6 5 3 0 5 3 3 0 
(ng) 
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5’-trfRNAGlu localizes to axons and presynaptic nerve terminals 
To confirm that 5’-trfRNAs are presynaptic SV-associated species, we performed 
fluorescent in situ hybridization on cryostat sections of the T. californica electric organ. 
Probes for 5’-trfRNAGlu or the SV transporter VAChT were used in association with 
fluorescently labeled α-Bungarotoxin, a postsynaptic marker for the nicotinic receptors 
that cover the surface of the electric organ. Nerve axons run perpendicular to the 
pancake stacked electric organ electrocytes before turning 90 degrees and innervating 
the entire surface of each cell.  We found that the probe for 5’-trfRNAGlu, but not a 
scrambled control probe, labeled the axons and surface of the electrocytes in a similar 
pattern as the presynaptic SV marker VAChT (Figure 12 a,b; Figure 13), suggesting 
that the 5’-trfRNAGlu is associated with axons and presynaptic nerve terminals rather 
than the postsynaptic electric organ. 
Synaptic vesicles isolated from mouse CNS contain RNA 
We hypothesized that synaptic vesicles residing in the CNS might also contain 
sRNAs. To test this, we isolated SVs from the mouse brain of Swiss Webster mice. As 
expected, the mouse brain SVs were ~40nm in diameter (Figure 14a) and the synaptic 
vesicle marker synaptophysin co-purified with SVs during isolation (Figure 14b; 
Figure 15). Once again, SVs were collected from the middle of the 0.6 M (1.07 g/ml 
density) sucrose gradient layer, well above the 1.2 M (1.17 g/ml) sucrose layer used to 
isolate exosomes130,131 or detect exosome markers132. We treated the mouse SVs with 
TRIzol and found that the preparation was enriched in sRNAs (Figure 14c). As with the 
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Figure 12. 5’-trfRNAGlu localize to axons and presynaptic nerve terminals of the 
electric organ of T. californica. a) Immunohistochemical labeling of 20-micron thick 
cryostat sections of the electric organ.  Axons and presynaptic terminals labeled with 
polyclonal antibodies against VAChT (red).  The nicotinic acetylcholine receptor rich 
surface of the electrocyte cells labeled with α-Bungarotoxin (green). a’) Enlarged region 
from A, axon marked with white arrow and presynaptic bouton white arrowhead  b) A 
similar pattern of labeling is present within in situ hybridization samples of the same 
tissue.  Axons and presynaptic boutons labeled with a probe for 5’-trfRNAGlu (red), and 
the surface of the electrocyte cells labeled with α-Bungarotoxin (green). b’) Enlarged 
region from B, axon marked with white arrow and presynaptic boutons white 
arrowheads  a’ and b’ scale bar = 5 µm. 
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Figure 13. In situ hybridization control demonstrating specificity of the 5’-trfRNAGlu probe 
versus scrambled probe. a) Cartoon depicting the orientation of cryostat sections of the electric 
organ shown in b-f. Stacks of electrocyte cells are on the left sides of each image, with the axon 
bundles  and a small amount of an adjacent stack of electrocytes shown on the right side of each 
panel. Right side panels (b,d,f) show three in situ preparations labeled with the scrambled probe. 
No appreciable labeling can be found on tissue sections. Left panels c,e show two additional in 
situ preparations labeled with the probe for 5’-trfRNAGlu.  Axons, running nearly perpendicular 
to electrocyte cells are visible (arrowheads), and strong staining of electrocyte surfaces 
(arrowhead) can be seen.  All images taken and balanced under identical conditions. Scale bar = 
5 microns. 
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RNA totals 
Electric organ SVs fish 1 
SV pH10 DM RNase pHDR 
SV starting material protein (mg) .75 .75 .75 .75 .75 
RNA recovered after treatment (ng) 8142 10092 8958 450 372 
Amount of RNA loaded into gel (ng) 
Fig 8c 452 560 498 375 310 
Average sample RNA (SV,pH10,DM) (ng) 9064 
After RNAse RNA (ng) 450 
Fraction RNA RNase resistant 0.05 
Electric organ SVs fish 2 
SV pH10 DM RNase pHDR 
SV starting material protein (mg) .81 .81 .81 .81 .81 
RNA recovered after treatment (ng) 4926 5598 5874 258 258 
Average sample RNA (SV,pH10,DM) (ng) 5466 
After RNAse RNA (ng) 258 
Fraction RNA RNase resistant 0.05 
Electric organ SVs fish 3 
SV pH10 DM RNase pHDR 
SV starting material protein (mg) .63 .63 .63 .63 .63 
RNA recovered after treatment (ng) 10284 10716 9492 372 486 
Amount of RNA loaded into gel (ng) 
Fig 2b 285 298 264 206 270 
Average sample RNA (SV,pH10,DM) (ng) 10164 
After RNAse RNA (ng) 372 
Fraction RNA RNase resistant 0.04 
 Table 8. Quantification of RNA from Torpedo californica experiment 
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T. californica SVs, we tested the mouse SV RNA under three conditions.  We raised the 
buffer to pH 10, but saw little difference. Next we added the detergent DM (also at pH 
10) and observed little difference between the RNA we isolated from the SV prep. When
we added RNase to the SV prep we had a dramatic reduction (~38 fold; Table 8) in the 
amount of total RNA extracted; however, two bands of resistant RNA at ~32 and ~21 nt 
remained.  These bands appear to be partially degraded when we combined pH 10, 
membrane detergent (DM), and RNase (Figure 14c). 
We sequenced the RNase resistant mouse SV sRNA using next generation 
sequencing. Two classes of sequences with slight variations of length dominated the 
reads, with the top ten sequences accounting for 40% of the total reads (Table 9). The 
most abundant set of sequences mapped to a 5’ fragment of a Y RNA: Ro-associated Y1 
(RNY1)127.  The 5’ fragment of RNY1 (5’-fRNY1) is part of the stem loop of RNY1, 
and like the 5’-trfRNAs, exists as multiple copies of similar length (~32nt). The second 
most abundant set of sRNAs in the mouse CNS SVs was the most abundant sequence 
found in the T. californica SVs: the 5’-trfRNAGlu (~32nt). The third, fourth, seventh, 
eighth and ninth mapped to neuronal associated microRNAs, including miR128, miR99, 
miR100, miR22, and miR127 (21-22nt). Fragments of other tRNAGlu species accounted 
for the fifth and sixth most abundant sequences. The fifth sequence does not map 
perfectly to any known mouse genomic sequence for a tRNA, perhaps as a result of a 
splice variation or mouse genomic strain difference, and the sixth most abundant 
sequence mapped to a fragment of tRNAGluTTC. The tenth most abundant sequence 
mapped to the 5’-terminal fragment of the 28s ribosomal RNA (20nt). These  
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Sequence NT Copy # Identity 
1 
GGCUGGUCCGAAGGUAGUGAGUUAUCUCA
AUU 32 4491149 RNA, Ro-associated Y1 
GGCUGGUCCGAAGGUAGUGAGUUAUCUCA
AU 31 3921692 
GGCUGGUCCGAAGGUAGUGAGUU 23 799788 
GGCUGGUCCGAAGGUAGUGAGUUAUCUCA 29 347449 
GGCUGGUCCGAAGGUAGUGAGUUAUCUCA
A 30 338822 
GGCUGGUCCGAAGGUAGUG 19 314918 
10213818 
2 
UCCCUGGUGGUCUAGUGGUUAGGAUUCGG
CG 31 2289788 5’-trfRNAGlu 
UCCCUGGUGGUCUAGUGGUUAGGAUUCGG
CGC 32 2039321 
UCCCUGGUGGUCUAGUGGUUAGGAUUCGG
C 30 882725 
UCCCUGGUGGUCUAGUGGUUAGGAUU 26 576141 
UCCCUGGUGGUCUAGUGGUUAGGAUUCGG 29 333204 
6121179 
3 UCACAGUGAACCGGUCUCUUU 21 2581783 MIR-128-1 
UCACAGUGAACCGGUCUCUUUU 22 1857626 
UCACAGUGAACCGGUCUCUUUUU 23 427156 
4866565 
4 AACCCGUAGAUCCGAUCUUGU 21 2055063 MIR-99a 
AACCCGUAGAUCCGAUCUUGUG 22 346662 
2401725 
5 
UCCCUGUGGUCUAGUGGUUAGGAUUCGGC
G 1488662 5’-trfRNAGlu 
6 
UCCCACAUGGUCUAGCGGUUAGGAUUCCU
GGUU 33 1087820 5’-trfNAGlu 
7 AACCCGUAGAUCCGAACUUGUG 22 545334 MIR-100 
AACCCGUAGAUCCGAACUUGU 21 350473 
895807 
8 AAGCUGCCAGUUGAAGAACUGU 22 716387 MIR-22 
9 UCGGAUCCGUCUGAGCUUGG 20 687125 MIR-127 
10 CGCGACCUCAGAUCAGACGU 20 609557 
rRNA-RNA, 28S 
ribosomal 5 
Table 9.  sRNAs identified through next-generation sequencing of SVs isolated 
from the mouse CNS. 
64 
nucleotides, along with the last 20nt of the 5.8s RNA, form the eukaryotic expansion 
segment known as ES4L, a double-stranded complex of the 60s ribosomal subunit141. 
We verified that the 5’-trfRNAs were not a result of the RNase treatment used in 
the isolation procedure by northern analysis with the 5’-trfRNAGlu sequence. The 
northerns were conducted three times, each with RNA isolated from a different 
preparation of mouse SVs. As with the T. californica, the 32nt 5’-trfRNAGlu is present in 
the mouse SV preparations before RNase treatment (Figure 14d). Unlike the T. 
californica SV preparation, full-length ~ 80 nt trfRNAGlu does appear to associate with 
synaptic vesicles prior to RNase degradation. In addition, we did not see an appreciable 
decline in signal for the 5’-trfRNAGlu after pH 10-DM-RNase treatment (Figure 14d; 
Figure 15). We can quantify the number of 5’-trfRNAGlu per SV from the mouse CNS 
using the weight of an average mouse SV (25.6 x 10-18 g/vesicle)142 and the amount of 
5’-trfRNAGlu detected in our northern analysis. We found that on average, 15 vesicles 
per 1000 would contain a 5’-trfRNAGlu if the sRNAs were evenly distributed (Figure 
16). In the northern analyses of the 5’ -fRNY1 RNA, multiple sizes representing full 
length and partial fragments of the RNY1 are associated with the SVs before RNAse 
treatment – ranging from shorter than 30nt to the full length 112 nt (Figure 14e; Figure 
17).  However, only the 32-nt 5’-fRNY1 RNA fragment is substantially enriched inside 
the SV and thus protected from RNase degradation. We found that on average, 142 
vesicles per 1000 would contain a 5’-fRNY1 if the sRNAs were evenly distributed 
(Supplemental Fig. 6). As with the 5’-trfRNAGlu, we did not see an appreciable 
degradation of the 5’-fRNY1 after pH 10-DM-RNase treatment.  We verified that the  
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Figure 14. SVs isolated from the mouse CNS contain sRNAs.  a) Electron micrograph image 
of negatively stained vesicles isolated from the mouse CNS. Sample contains abundant ~40 nm 
vesicles (some marked with arrows). b) Western-blot analysis of the synaptic vesicles during 
purification.  The SV protein synaptophysin was used as a marker during isolation. The isolation 
procedure includes the collection of the orginal slurry (Sl), two centrifugation supernatants and 
pellets (S1, P1 and S2, P2), followed by a sucrose density gradient centrifugation and collection 
of the SV fluffy layer (FL).  Further purification using size exclusion chromatography yields the 
final, isolated sample of SVs (SV). c) Abundant sRNAs co-enrich with the synaptic vesicles 
(SV).  These sRNAs are stable under high pH (pH10), or in the presence of detergent (DM).  
After addition of RNase much of the RNA is degraded; however an RNase resistant ~32 nt and 
lower ~20 nt band persists (RNAse).  The RNAse resistant band of RNA can be partially 
degraded in the presence of high pH, detergent, and RNAse (pHDR). d) Northern analysis of 
RNA isolated from SVs verifies that the 5’-trfRNAGlu sequence, the second most abundant 
sequence in mouse CNS SV, was not a product of RNase treatment. RNA isolated from SVs 
purely isolated (SV), at pH10 (pH10), in detergent (DM), treated with RNase (RNase), and 
treated simultaneously with pH10, detergent, and RNase (pHDR).  In the mouse CNS, both full-
length tRNAGluCUC and 5’-trfRNAGlu co-enrich with the SVs, but only 5’-trfRNAGlu is resistant to 
RNase treatment. e) The most abundant species of sRNA in mouse was a 5’ fragment of a Y 
RNA: Ro-associated Y1 (RNY1): 5’-fRNY1. Like the 5’-trfRNAGlu, full length and precursor 
sequences of RNY1 co-enrich with the SVs. c-e) Bands of gel underlined (_) indicate a 20-fold 
reduction of sample loaded. f) The miRNA and RISC associated protein AGO2 co-enriches with 
SVs, however it is susceptible to trypsin degradation (0-20 minute exposure) indicating it does 
not reside within the lumen of the SVs.  The SV protein synaptophysin, which has trypsin 
cleavage domains residing within the lumen of the SVs, is not degraded. 
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Figure 15.  Northern quantification based upon positive control of the 5’-
trfRNAGlu. Control and quantified using ImageQuant. Left Figure – Used for 
publication; no control fragment was loaded in gel.  Right Figure.  Gel with similar 
loaded volume and control used as a basis for quantification.   
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SV pH10 DM RNase pHDR 
RNA recovered after treatment (ng) 9114 11910 11136 300 324 
Amount of RNA loaded into gel (ng) 253 330 309 200 165 
Northern Analysis 
Amount of tRNA in northern (ng) 1.5 0.7 1 0 0 
Calculated amount of tRNA after isolation (ng) 36 16.8 24 0 0 
Amount of 5’-trfRNAGlu in northern (ng) 1.2 2 2.5 10 14 
Calculated amount of 5’-trfRNAGlu after isolation (ng) 29 28 60 15 27 
Amount of tRNA before RNAse 25.6 
Amount of 5’-trfRNAGlu before RNAse 39 
Fraction of 5’-trfRNAGlu RNAse resistant 0.25 
Amount of SVs (g) 
8.4 x 
10-4
Number of Vesicles 
3.28 x 
1013 
Number of 5’-trfRNAGlu (10ng) 
3.73 x 
1011 
Copies of 5’-trfRNAGlu per vesicle 0.015 
Table 10. The number of synaptic vesicles in Figure 15 can be estimated based upon 
the amount of vesicles used in the preparation (grams) and the published molecular 
weight of mouse CNS synaptic vesicles (25.6 x 10-18 g/vesicle)142.  Likewise the 
amount of RNAse resistant copies of 5’-trfRNAGlu per vesicle can be estimated 
based upon molecular mass of 5’-trfRNAGlu and the amount found in the northern. 
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Figure 16. Western-blot analysis of the synaptic vesicles during purification.  The 
Endoplasmic reticulum protein Calnexin and the Golgi apparatus marker 58k protein 
were used as markers during the purification. The isolation procedure includes the 
collection of the original slurry (Sl), two centrifugation supernatants and pellets (S1, P1 
and S2, P2), followed by a sucrose density gradient centrifugation and collection of the 
SV fluffy layer (FL).  Further purification using size exclusion chromatography yields 
the final, enriched sample of SVs (SV).  Vesicle preparation appears to contain little to 
no Calnexin or 58K protein.  As a further control, SVs were isolated using an alternative, 
synaptosomal-based strategy, and found to contain sRNAs of similar length (Figure 
18b).  
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Figure 17.  Northern quantification of 5’- fRNY1 in sample based upon positive 
control of the 5'-fRN Control loaded into the gel and quantified using ImageQuant. 
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SV pH10 DM RNase pHDR 
Sample total (ng) 9114 11910 11136 330 408 
Sample loaded (ng) 253 330 309 183 226 
Northern Analysis 
Amount of 5'fRNY (ng) in northern n/a n/a n/a 71 113 
Calculated amount of 5'-fRNY after 
isolation (ng) n/a n/a n/a 129 205 
Amount of SVs (g) – see Sup Table 2 8.4 x 10-4 
Number of Vesicles 3.28 x 1013 
Number of 5’- fRNY1 (129ng) 4.65x 1012 
Copies of 5’- fRNY1 per vesicle 0.142 
Table 11. Quantification of Figure 17 using ImageQuant. The number of synaptic 
vesicles can be estimated based upon the amount of vesicles used in the preparation 
(grams) and the published molecular weight of mouse CNS synaptic vesicles (25.6 x 10-
18 g/vesicle)142.  Likewise the amount of RNAse resistant copies of of 5’- fRNY1 per 
vesicle can be estimated based upon molecular mass of of 5’- fRNY1 and the amount 
found in the northern. 
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RNAse cocktail was capable of degrading all of the sRNA in the sample by first 
isolating the RNase resistant RNA with Trizol followed by a treatment of RNase.  Once 
separated from the SV, all of the sRNAs were degraded (Figure 18). We did not find 
any complementary sequences to the 20-21 nt miRNAs found within the SVs, suggesting 
the miRNAs present are single stranded.  We tested whether the miRNAs that reside 
within the SVs might be associated with argonaute-2 (AGO2), as a previous study found 
AGO2 associated with enriched SVs 126. AGO2 bound to miRNAs can form the minimal 
RNA-induced silencing complex (RISC)143. We found that AGO2 was associated with 
our SV preparation. To test whether AGO2 resided within the SVs, or was associated 
with the exterior of the SVs, we treated the sample with the protease trypsin.  We 
hypothesized that much like the RNase resistant sRNAs, AGO2 would be protected from 
degradation if it resided within the SVs.  AGO2 was not protected from degradation, 
suggesting the miRNAs present are not associated with AGO2 (Figure 14f). To verify 
that we were not inducing the degradation of the vesicles with the application of trypsin 
we also tested for the degradation of synaptophysin. Synaptophysin can be cleaved by 
trypsin, but the trypsin cleavage sites reside within the lumen of the SVs. Synaptophysin 
was not degraded in the trypsin treated samples (Figure 14f).  That AGO2 is associated 
with the isolated SVs raised the possibility that some of the RNase and detergent 
resistant sRNAs might be in an AGO2 associated complex.  To test that hypothesis we 
treated SVs with trypsin for 20 minutes, followed by trpsin inhibitor and RNase.  The 
sRNAs were resistant to the trypsin treatment (Figure 18).  As an additional test we  
73 
Figure 18. RNase and Trypsin sensitivity, and alternative SV isolation procedure. 
a) Abundant sRNAs co-enrich with the synaptic vesicles (SV). After addition of RNase
much of the RNA is degraded; however an RNase resistant ~32 nt band persists 
(RNAse). If the RNAse resistant RNA is isolated by TRIzol first, and then subjected to 
another round of RNase treatment, the RNA shows sensitivity to RNase and is degraded 
(Isolated RNA RNase). Bands of gel underlined (_), 20-fold reduction in loading b) SVs 
isolated by an alternative isolation procedure possess sRNAs. Vesicles were isolated 
following the synaptosomal isolation procedure following Ahmed et al.144 Isolated SVs 
were then treated with RNase as described - sRNAs of similar nt length can be seen 
(RNAse). c) sRNAs are resistant to trypsin treatment. SVs untreated shown in (SV), 
after trypsin treatment for 20 minutes (Trypsin), trypsin treatment for 20 minutes 
Trypsin followed by trypsin inhibitor and RNase (Trypsin and RNase), or trypsin 
treatment for 20 minutes in the presence of the membrane detergent DM, followed by 
trypsin inhibitor and RNase (Trypsin & RNase and DM). The RNase resistant sRNAs 
persisted - northerns for both  (d) 5’-trfRNAGlu and (e) 5’-fRNY1 demonstrate that the 
sRNAs were not affected by prior treatment with trypsin, and the addition of DM did not 
lead to degradation of either sRNA. The PBS perfused mouse brains used in (b) were 
kindly provided by Matthew Lee and Mendell Rimer under protocols approved by the 
IACUC of Texas A&M University. 
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treated the SVs with trypsin in association with the membrane detergent DM for 20 
minutes before addition of trypsin inhibitor and RNase treatment.  The RNase resistant 
sRNAs persisted - northerns for both 5’-fRNY1 and 5’-trfRNAGlu demonstrated that the 
sRNAs were not affected by prior treatment with trypsin, and the addition of DM had no 
effect (Figure 18). 
What is the structure of 5’-trfRNA? 
In an effort to gain insight into the molecular mechanism of 5’-trfRNAGlu, we 
examined the predicted structure of 5’-trfRNAGlu through computational approaches. We 
used RNAfold 145 to calculate the optimal secondary structure of the minimum free 
energy (MFE) of the sequence (Figure 19a). We found that MFE of the optimized 
secondary structure was -5.20 kcal/mol.  The free energy of the thermodynamic 
ensemble was -5.37 kcal/mol, with a frequency of the MFE structure in the ensemble of 
76% (Figure 19a). A similar centroid secondary structure was calculated with a MFE of 
-5.20 kcal/mol. Based upon this secondary structure we calculated a tertiary structure of 
the 5’-trfRNAGlu using RNACOMPOSER 146. Surprisingly, the stem and loop structure 
determined in this manner closely resembled known crystal structures of the tRNA 
anticodon stem and loop, particularly at the anticodon region (Figure 19d), even though 
the tRNAGlu anticodon from the full-length tRNA is not in the 5’ tRNA fragment. The 
sequence of this pseudo-anticodon is GGU and thus would recognize threonine codons, a 
codon not present in vertebrate genomes. 
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Figure 19. Tertiary structure of 5’-trfRNAGLU mimics tRNA anticodon stem and 
loop.  a) RNAfold was used to calculate the minimum free energy secondary structure of 
5’-trfRNAGlu.  Base-pair probabilities are shown in a heat map from 0-1; for non-paired 
nucleotides, heat map indicates probability of being unpaired. b) The centroid secondary 
structure is identical to the minimum free energy structure.  The heat map shows the 
positional entropy (from 0 - 1.1).  c) Secondary structure of 5’-trfRNAGlu showing the 
pseudo-anticodon region in orange. d) Tertiary structure of 5’-trfRNAGlu calculated 
using RNACOMPOSER (red and orange).  The tertiary structure was aligned in pymol 
to a known crystal structure of a tRNA, shown in blue (yeast tRNAPhe 1ehz) The stem 
and loop structure determined in this manner closely resembled known crystal structures 
of the tRNA anticodon stem and loop, particularly at the anticodon region (orange). The 
sequence of this pseudo-anticodon is GGU. Both RNAfold and RNACOMPOSER used 
with default settings. 
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In this study, we demonstrated that cholinergic SVs isolated from the PNS 
electroplaque of T. californica contain sRNAs (Figure 8c). Single vesicle imaging of  
RNase treated SV preparations from T. californica demonstrated that membrane bound 
structures co-labeled with probes for membrane, for cholinergic neurotransmitter 
transporter VAChT, and for RNA (Figure 8d). We immunopurified T. californica SVs 
using antibodies against VAChT.  We then isolated RNase resistant sRNAs from these 
vesicles.  Next generation sequencing showed that these sRNAs consisted primarily of 
5’-tRNA fragments, with 5’- trfRNAGlu being the most abundant (Table 5). We 
demonstrated by northern analysis that the 5’- trfRNAGlu was not a byproduct of RNase 
treatment (Figure 7b), and that it exists as both a full-length tRNAGluCUC and a 5’-
trfRNAGlu in the T. californica PNS, and in the electric lobe, the location within the CNS 
of the cell bodies of the electromotor neurons (Figure 8c). In addition, we demonstrated 
by northern analysis that the signal representing 5’- trfRNAGlu in the T. californica SV 
preparation could only be reduced below detectable levels in the presence of detergent, 
high pH, and RNase (Figure 8b), suggesting that this RNA resides within the vesicles. 
In situ hybridization of the 5’- trfRNAGlu sequence was consistent with 
immunohistochemical labeling of the SV marker VAChT in cryostat sections of the T. 
californica electric organ (Figure 9a,b).  
We extended our findings to heterogeneous SVs isolated from the mouse brain. 
We found that these mouse brain SVs also contain sRNAs, the most abundant of which 
is a 5’ fragment of the RO associated Y1 RNA, we term 5’-fRNY1 (Table 6). The 
second most abundant sRNA sequence in SVs isolated from the mouse brain is the 5’- 
Discussion 
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trfRNAGlu.  We demonstrated by northern analysis that the 5’-fRNY1 and the 5’- 
trfRNAGlu were not a byproduct of RNase treatment (Figure 14d,e), i.e. we found that 
precursors for both fragments exist, but are degraded by RNase treatment, suggesting 
they do not reside within the SV lumens. One potential interpretation for the presence of 
the precursors in association with the SVs is that the presynaptic terminal is a site of 
cytoplasmic maturation and cleavage of SV sRNAs. Finally, we demonstrated by 
northern analysis that the signals representing the 5’-fRNY1 and 5’- trfRNAGlu in the 
mouse CNS SV preparation were RNase resistant (Figure 14d,e) - even if the SVs were 
treated with trypsin (Figure 15). We do not have an explanation for the persistence of 
the mouse sRNAs in detergent and RNase compared to the T. californica sRNAs 
sensitivity to the same treatment.  The smaller size of the mouse SVs may make them 
less soluble in detergent, or the sRNAs are in a trypsin resistant complex in the mouse 
SVs. 
The most abundant sRNA present in T. californica SVs, as well as a large 
percentage of the sRNAs present in mouse SVs (second, fifth and sixth most abundant), 
were previously identified as stress-induced tRNA fragments (Table 5, 6).  Two 
pathways are known to produce these fragments in vertebrates. 5’-trfRNATyr arises by 
induced RNA pol III transcription in response to H2O2 147. A second pathway for the 
production of 5’-trfRNAs is by the stress-induced RNase angiogenin138,139,148. 
Angiogenin has been shown to be involved in the fragmentation of tRNAGluCUC into 5’-
trfRNAGlu in airway epithelial cells after viral infection and induce stress granule 
formation and suppress protein translation in a miRNA and siRNA independent manner 
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86. Whether a similar mechanism occurs at the synapse, or in other tissues shown to be 
enriched in 5’-trfRNAGlu and 5’-trfRNAGly is not known149. We calculated a tertiary 
structure of the 5’-trfRNAGlu using RNACOMPOSER 146, which predicted a stem and 
loop structure that closely resembled known crystal structures of the tRNA anticodon 
stem and loop (Figure 10d). If 5’-trfRNAGlu does alter translation in a miRNA and small 
interfering RNA (siRNA) independent manner, perhaps it does so by directly interacting 
with the protein translation machinery by mimicking the anti-codon stem loop of a 
tRNA. 
In this paper we focused on the isolation and localization of sRNAs isolated from 
SVs of two different organisms, the PNS of T. californica and the CNS of mouse. The 
most abundant sequences of sRNAs isolated and sequenced were over 30nt; however, 
we did isolate and sequence miRNAs in the 20-21nt range, including miR128, miR99a, 
miR100, miR22, and miR127.  The most abundant miRNA, and the third most abundant 
class of sequences was miR128, a miRNA important for neuronal development, 
synaptogenesis, and post-mitotic neuronal functioning150.  Members of the miR-99 
family (miR99a, and miR100, the fourth and seventh most abundant mouse sRNAs) are 
miRNAs that have been shown to co-enrich with polyribosomes in mammalian neurons, 
and regulate the mammalian target of rapamycin (mTOR) pathway151. miR22, the eighth 
most abundant mouse sRNA, is important for cerebellar development, and in adults has 
been shown to protect neurons from neurodegeneration, and is down regulated in both 
Huntington’s and Alzheimer’s disease 152.  miR127, along with a cluster of miRNAs 
found on chromosome14q32, is maternally expressed, and the down regulation of 
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miRNAs within this cluster (including miR127) has been linked to schizophrenia153. The 
mechanism by which miRNAs are taken in at the synapse is not known. However, a 
previous study has demonstrated that miR99a is released from synaptosomes in an 
activity and calcium dependent manner, consistent with the release from SVs, and 
synthetic miRNAs were taken up by synaptosomes via an unspecified endocytic 
pathway126. 
           Long-term changes in synaptic plasticity require protein synthesis, the local 
dendritic regulation of which is still an active area of research 69,120-122. One common, 
and critical component of every model of local protein synthesis is the role activity plays 
in up-regulation and down-regulation of translation. Activity at a local synapse is driven 
by the presynaptic fusion of synaptic vesicles with the plasma membrane, and the 
subsequent release of the contents residing within the SV lumen. Currently most of our 
understanding of SV content release has focused on small molecule neurotransmitters 
that rapidly bind metabotropic and ionotropic receptors leading to near instantaneous 
changes in target membrane excitability. Given the immense specificity and wide 
ranging effects that sRNAs can exert on transcription and translation123,154,155, the precise 
molecular control with which SVs link presynaptic activity to SV content release, and 
the developmental precision with which the pre and postsynaptic apparatus are spatially 
aligned at every type of synapse, the addition of sRNAs to the list of molecules released 
by SVs during exocytosis, and/or possibly taken up by SVs during endocytosis, is both 
powerful and exciting. It provides the potential for a direct means of controlling 
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translation locally, which may prove at least as important as the proposed calcium 
induced mechanisms for controlling translation. 
Materials and Methods 
Isolation and enrichment of synaptic vesicles 
Methods were adapted from Ohsawa102. Three preparations of electric organ with 
tissue from 3 separate Torpedo californica fish (2 female, 1 male), and three 
preparations of mouse brains (approximately 50 mouse brains of both male and female 
per each preparation) were used during these studies. A Spex Freezer Mill 6800 (Spex 
Sample Prep; Metuchen, NJ) was cooled to -180°C and ~25 g of frozen electric organ 
from an individual (Aquatic Research Consultants; San Pedro, CA) or 25g frozen Swiss 
Webster mouse brains (BioChemed Services, Winchester, V.A.) was ground with 25 g 
of frozen buffer pellets (320 mM Sucrose, 10 mM TRIS-Cl, pH 7.4) (Sigma-Aldrich; St. 
Louis, MO). The resulting powder of buffer and electric organ/brain was warmed to 4°C 
with 50 ml of buffer solution (320 mM Sucrose, 10 mM Tris-Cl, pH 7.4, 4°C). The 
resulting slurry (100 ml) was centrifuged at 20,000 rpm for 10 minutes (Beckman 
Coulter JA-20 rotor  - Avanti J25 centrifuge) (Beckman Coulter; Brea, CA).  The 
resulting supernatant was centrifuged at 34,000 rpm for 40 minutes (70ti rotor - Optima 
X80; Beckman). The supernatant was then loaded onto a 4ml/4ml 0.6 M/1.2 M sucrose 
step gradient (10 mM Tris-Cl, pH 7.4), then centrifuged at 48,000 rpm for 2 hours (70ti 
rotor - Optima X80).  The 4 ml 0.6 M (1.07 g/ml density) sucrose fluffy layer, enriched 
in vesicles, was collected.  Heavier densities and pellet (> 0.6M sucrose), known to be 
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enriched in exosomes, were discarded130,132. A 2 ml sample of enriched vesicles was 
filtered using a 0.22 µm spin column (Spin-x, Corning; Corning, NY) to remove any 
large debris.  The filtrate was injected into a Pharmacia LC500 plus FPLC (GE 
Healthcare, Fairfield, CT) and run through a 25 cm 4% agarose bead column (Bioscience 
Beads; West Warwick, RI).  Separate bead columns were prepared for electric organ and 
mouse brains to ensure no contamination. The FPLC was eluted with a buffer solution 
PBS, pH 7.4 at a flow rate of 1.0 ml/min. The second major peak was collected, and the 
vesicles concentrated to a protein concentration of 5 mg/mL (measured by Bradford 
Assay)(Bio-Rad Laboratories, Inc.; Hercules, CA) using a Stirred Cell apparatus with a 
100 kDa filter (PLHK02510; Millipore, Billerica, MS). 
Electron microscopy 
Negative stain of isolated synaptic vesicles of T. californica and mouse are 
conducted following Jahn and Maycox103 . Briefly, A 5 µl sample of enriched synaptic 
vesicles (further concentrated to 20 mg/ml with Pierce concentrator, PES, 100K MWCO 
(88503, Thermo Scientific) as determined by Bradford assay was pipetted onto a slot 
grid. Excess sample was removed by filter paper, and the grid was briefly washed in 
12mM sodium phosphate buffer, followed by 2 s staining with uranyl acetate (Ted Pella; 
Redding, CA), followed by another wash103. The slot grid was viewed with a JEOL 1200 
JEOL Ltd., Akishima-Shi, TKY Japan) operated at 100 kV. Image was collected at 
50,000 X magnification on a bottom-mounted 3072 x 3072, slow scan, lens-coupled 
CCD camera SIA 15C (SIA; Dulith, GA). 
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Synaptic vesicle lysates were loaded on to a 4–20% SDS-PAGE gel (456-9034; 
BioRad) and blotted using standard protocols.  All gel lanes were loaded with equal 
volume (3µl) of sample. Primary antibodies against synaptophysin (1:1000; MAB5258; 
EMD Millipore, Billerica, MA), AGO2 (1:1000; ab186733; Abcam, Cambridge, 
England), VAChT (1:1000; ab68986; Abcam), 58K (1:1000; ab19072; Abcam), and 
Calnexin (1:1000; ab22595; Abcam). Secondary antibodies were HRP-conjugated goat-
anti rabbit (1:2000; 2-348; EMD Millipore), rabbit anti-goat (1:2000; 6020-05, Southern 
Biotech; Birmingham, AL), and goat-anti mouse (1:2000; ab5879; Abcam). 
Visualization of blots was conducted with ECL Prime (RPN2232; GE Healthcare) 
according to manufacturer’s instructions. Chemiluminescence was quantified using a 
Chemicdoc XRS+ Imager with Imagelab software (BioRad). 
Synaptic vesicle RNA isolation and tRNA isolation 
SVs were isolated and concentrated as described above.  For each assay, 1 
preparation of vesicles was utilized and split into 5 equal samples. Each sample 
consisted of 3 x 50 µl of SVs (5 mg/ml) in PBS (80 mM Na2HPO4 and 25 mM 
NaH2PO4, 100 mM NaCl pH 7.4; Sigma). The 5 parallel treatments conducted on the SV 
preparations were: 1) addition of 50 µl PBS, pH 7.4, 2) addition of 50 µl PBS pH 11 
(adjusted with NaOH; Sigma), 3) addition of 50 µl PBS pH 11 and 100 mM membrane 
detergent DM (n-Decyl-β-D-Maltopyranoside, D322; Anatrace, Maumee, OH), 4) 
Addition of 50 µl PBS pH 7.4 with 1 µl RNase cocktail as instructed (RNase A (500 
U/ml) and RNase T1 (20,000 U/ml), AM2286; Ambion/Life Technologies), and finally 
5) addition of 50 µl combined pH 11, DM, and RNAse treatments.  RNA was extracted
Western blots 
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after the treatments using 900 µl TRIzol (Invitrogen/Life Technologies) followed by 200 
µl chloroform and 400 µl isopropanol (EMD Millipore), with a final precipitation by 
75% ethanol.  The total SV RNA was resuspended in 6 µl of DI water, and the three 
samples of each treatment were quantified – Supplemental Tables show combined 
results. 
RNA concentration was determined using QuantiFluor RNA System (E3310, 
Promega, Madison, WI) and Quantus Fluorometer (E6150, Promega).  Briefly, 1 µl of 
isolated RNA is dissolved for 5 minutes in 199 µl of Master solution (20X TE Buffer, DI 
water, and QuantiFluor RNA dye); the solution was then read in the Quantus 
Fluorometer. 
 To isolate total RNA from the electric lobe (CNS) and electric organ (PNS) of T. 
californica, 100 mg of tissue of each organ was dissected and ground with silica beads 
before RNA extraction by TRIzol (described above).  For further enrichment of sRNA 
and tRNA, samples of total RNA were resuspended in 300 µl of 10 mM sodium acetate 
(Sigma-Aldrich) pH 4.5 at 4°C, and mixed with 30 µl of 8 M LiCl (Sigma-Aldrich).  
After centrifugation at 15,000 g, 4°C, the tRNA and sRNA is collected from the 
resulting supernatant. 
Fluorescent immunohistochemical labeling of isolated synaptic vesicles and TIRF 
imaging of single vesicles 
Isolated SVs were passed through a 0.22 µm spin column, and 100 µl of synaptic 
vesicles (1 mg/ml) were transferred into 300 µl PBS (pH 7.4), and labeled with one 
round of primary and secondary antibody following the procedure101. Briefly, the 
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vesicles were incubated for overnight with 1 µg of VAChT antibody in 4°C, incubated 
for 30 min with 20 µl anti-rabbit IgG beads (Sigma-Aldrich), briefly centrifuged, and the 
vesicle containing supernatant was then incubated with 0.5 µg goat anti-rabbit secondary 
antibody labeled with Pacific Blue (P-10994, Life Technologies) for 4 hours before 
finally being incubated with 20 µl anti-goat IgG beads (Sigma-Aldrich). The beads were 
pelleted and the supernatant collected for imaging. SVs were incubated in RNase 
cocktail for 30 minutes.  
FM4-64104 and SYTO 12 (S7574; Life Technologies) were added to the labeled 
vesicles (final concentration 1 µM), and the samples were settled on a glass bottom 
culture dish (MatTek P35G-1.5-20-C; Ashland, MA) for at least 1 hour. Settled vesicles 
were imaged with a Zeiss Axio Observer Z1 Microscope with TIRF slider, 100X TIRF 
objective (NA 1.45). Images were acquired using AxioVision (Carl Zeiss; Oberkochen, 
Germany). Three separate images from each field were taken using laser lines and filter 
cubes paired to eliminate fluorescent cross talk between the dyes: laser line 401 with 
filter cube 73 HE was used for Pacific Blue, laser line 488 with filter cube 38 HE was 
used for SYTO 12, and laser line 561 with filter cube 74 HE was used for FM 4-64. 
Images were collected with a Roper S/W PVCAM EMCCD camera and analyzed using 
ImageJ (NIH, Bethesda, MA) software.  Suitable spots detected in the FM4-64 channel 
were marked.  The other channels were then quantified for label.   
RNA gels and northern blots 
Electrophoresis and blotting are previously described140. Denatured RNA 
samples were run through 10% TBE Urea precast gel (BioRad, 456-6033).  Because of 
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resulting sample differences in yield between non-RNAse treated and RNAse treated SV 
RNA preparations, gel lanes loaded with non-RNase treated samples were reduced by 
~20-fold to match the amount loaded in the RNase treated lanes as described in figure 
legends and documented in supplemental materials. Northern blots were conducted in 
triplicate, in order to reduce bias from any single preparation, each northern was 
conducted on RNA isolated from a single fish.  For mouse brain SVs, three separate 
preparations of SV RNAs were isolated in order to perform northerns in triplicate. 
Northern blots were transferred to Zeta Probe Blotting Membrane (BioRad, 162-0153) in 
1xTBE buffer at 20V for 90min. The membrane was rinsed with 5xSSC buffer and 
RNAs were crosslinked to the membrane using a Stratalink UV crosslinker (auto 
setting). The membrane was incubated in a hybridization tube with 15ml of 
prehybridization buffer at 42°C for 3 or more hours. 50 pmol of oligo was radioactively 
labeled using 300 µCi [gamma32-P] ATP (NEG502A; Perkin Elmer; Waltham, MA) and 
T4 Polynucleotide Kinase and the signal was detected by autoradiography. Denatured 
probe (heated at 95°C for 5 min and chilled on ice) was added to the hybridization tube, 
and incubated at 42°C overnight. The membrane was washed with 100ml 2xSSC/0.1% 
SDS and then with 100ml 0.2xSSC/0.1% SDS at room temperature for 5 min, 
respectively. The membrane was washed at 42°C with 100ml 0.2xSSC/0.1% SDS for 30 
min and then at 68°C with 100ml 0/1xSSC/0.1% SDS for 30 min. The membrane was 
dried and then exposed to a storage phosphorplate (GE Healthcare) for 16 h before being 
scanned with a Typhoon Trio Variable Mode Imager  (GE Healthcare) and quantified 
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based upon binding of probe to positive control loaded sample of known quantity using 
ImageQuant TL software (GE Healthcare).  
20xSSC buffer: 3M sodium chloride, 300mM sodium citrate 
prehybridization buffer: 0.75M NaCl, 50mM NaPO4, 5mM EDTA, 1%SDS, 50% 
formamide, 0.2% BSA, 0.2% polyvinylpyrollidone 40, 0.2% Ficoll 400 (Sigma) 
trfRNAGlu – probe 5’- CGCCGAATCCTAACCACTAGCCACCA 
trfRNAGlu – positive control in vitro transcription 
5’-TAATACGACTCACTATAGGTCCCTGGTGGTCTAGTGGTTAGGATTCGGCGC 
5’-GCGCCGAATCCTAACCACTAGACCACCAGGGACCTATAGTGAGTCGTATTA 
Ro Y1 – probe 5’ -AACTCACTACCTTCGGACCAGCC 
Ro Y1 – positive control in vitro transcription 
5’-TAATACGACTCACTATAGGGGCTGGTCCGAAGGTAGTGAGTT 
5’- AACTCACTACCTTCGGACCAGCCCCTATAGTGAGTCGTATTA 
RNA isolation and sequencing 
SVs from T. californica and mouse whole brain were isolated and treated with 
RNAse cocktail (Ambion/Life Technologies) as described above. As a further 
enrichment, SVs from T. californica were affinity enriched using dynabeads (100.07D; 
Dynabeads; Invitrogen/ Life Technologies) with VAChT antibody131,137. The total RNA 
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was extracted following the TRIzol procedure described above. Library preparation and 
sequencing were performed by the Genomic Sequencing and Analysis Facility at the 
University of Texas, Austin. The samples were prepared for sequencing using the 
TruSeq small RNA sample preparation kit (Illumina; San Diego, CA).  Single-end reads 
(100bp) were sequenced on an Illumina HiSeq 2500(Illumina). 
trfRNA in situ hybridization 
For in situ hybridization (ISH), frozen T. californica electoplaque was 
cryosectioned (30-40 µm) and mounted onto Superfrost Plus slides (VWR, Radnor, PA). 
Fluorescein-labeled anti-sense morpholino oligomer probe matching coding 5’-
trfRNAGlu was synthesized from Gene Tools (Philomath, OR). Control fluorescein-
labeled anti-sense cRNA probes matching coding 5’-trfRNAGlu and scrambled were 
synthesized from IDT (Coralville, IA). Probes were hybridized to sections as previously 
described 156, with minor modifications in amplification strategy. Following overnight 
hybridization, slides were incubated with alkaline phosphatase conjugated anti-
fluorescein antibody (1:5000; 11426338910; Roche Life Sciences, Indianapolis, IN) for 
overnight at 4°C. Tissues were washed and incubated in Fast Red (11496549001; Roche 
Life Sciences) according to manufacturer's instructions for overnight at 4°C in dark. 
Confocal images were captured with a Zeiss 780 Structure Illumination microscope 
(Zeiss, Germany). Sequences used for probe generation are listed below. 
trfRNAGlu Morpholino:  5’- GCCGAATCCTAACCACTAGACCACC-fluoroscein 
trfRNAGlu DNA control: 5’- GCCGAATCCTAACCACTAGACCACC-fluoroscein 
trfRNAGlu DNA scramble: 5’ - CCCGAATCGTAACGACTAGAGCAGC-fluoroscein 
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Trypsin sensitivity 
AGO2/synaptophysin Westerns: SVs were isolated and concentrated as described 
above. One preparation of vesicles was split into 10 equal samples. Each sample 
consisted of 5 µl of SVs (6 mg/ml) in PBS, pH 7.4. Paired samples were treating in the 
following manner: no Trypsin treatment, 2µl Trypsin (T1426, 10mg/ml; Sigma-Aldrich) 
treated for 5 mins, 10 mins, 20 mins or 30 mins. Westerns were conducted using 
antibodies against synaptophysin or AGO2. 
SV RNA sensitivity to Trypsin: SVs were isolated and concentrated as described 
above.  For each assay, 1 preparation of vesicles was utilized, and split into 4 equal 
samples of 50 µl. Each sample consisted of SVs (6 mg/ml) in PBS (80 mM Na2HPO4 
and 25 mM NaH2PO4, 100 mM NaCl), pH 7.4. The 4 parallel treatments conducted on 
the SV preparations were: 1) addition of 50 µl PBS, pH 7.4, 2) addition of 50 µl PBS pH 
7.4 and 0.5 µl Trypsin (T1426,10mg/ml; Sigma-Aldrich) for 20 minutes, 3) addition of 
50 µl PBS pH 7.4 and 0.5 µl Trypsin for 20 min, followed by 5 µl Trypsin Inhibitor 
(T9128, 6.5mg/10ml, Sigma-Aldrich) and 1µl RNAse for 30 min., 4) addition of 50 µl 
combined Trypsin, 200mM DM for 20 min, followed by 5 µl Trypsin Inhibitor and 
RNAse treatment for 30 minutes. RNA was extracted after the treatments and quantified 
as described above. 
Prediction of 5’-trfRNAGlu structure 
The secondary structure of the 5’-trfRNAGlu was predicted using the default 
settings of RNAfold 145 (ViennaRNA Package 2.0;Theoretical Biochemistry Group, 
University of Vienna Wien, Austria). The resulting secondary structure was used to 
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calculate a predicted tertiary structure using the default settings for RNACOMPOSER 
146 (Institute of Computing Science, Poznan University of Technology, Poznan Poland).  
Visualization of the structure was conducted using the MacPymol Molecular Graphics 
System, Version 1.7.4 (Schrödinger, LLC; Cambridge, MA) running on a Mac Pro with 
OS 10.9.5 (Apple; Cupertino, CA). 
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4. CONCLUSIONS AND FUTURE WORK 
 
In the previous section, I proposed that synaptic vesicles contain small 
ribonucleic acids (sRNAs), including transfer RNA fragments (trfRNA) and microRNAs 
(miRNA) known to be involved with post-transcriptional regulation. Moreover, I 
hypothesized that the activity-based release of these molecules, along with 
neurotransmitter, may be an important regulator of local protein synthesis at the synapse. 
In this section, I will outline several key questions about SV sRNAs and propose 
potential experiments that could address some of these questions. 
The Biogenesis of Synaptic Vesicle sRNAs  
The origins of the SV trfRNAs are currently unknown. The most prominent 
trfRNA I discovered is predicted to be a 5’ fragment of a glutamyl-tRNA; however, 
whether this tRNA is ever used during protein translation is not known. Bioinformatic 
analysis predicts that there are multiple tRNAs with the same anti-codon region in all 
vertebrate genomes, but there is little experimental evidence as to which of these tRNAs 
are actually used to transport amino acids to the ribosome during protein translation157. 
Functional tRNAs possess multiple modifications to their chemical backbone subunit, 
such as 2-methyladenosine and agmatidine158,159.  These modifications are enzymatically 
regulated during tRNA biogenesis. If the 5’-trfRNAGlu discussed in the previous section 
is cleaved from a functional tRNA, it should possess post-transcriptional modifications 
to its chemical backbone. Thus, to address whether the 5’-trfRNAGlu was ever a 
functional tRNA, I would test whether the trfRNAs in the isolated synaptic vesicles have 
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such backbone modifications. To detect these modifications, I propose the use of mass 
spectrometry. Mass spectrometry is an analytical technique that can identify and 
quantify molecules present in a sample. By combining mass spectrometry with 
endonuclease treated samples of our SV sRNAs, I can test for the presence of modified 
nucleotides. Sample preparation is summarized briefly. Isolated sRNAs can be further 
purified through RNA gel electrophoresis, and the specific band where the 5’-trfRNAs 
resides can be isolated. To detect any modifications, the sample can be digested with a 
RNase cocktail that will reduce the RNA molecules into individual nucleotides. 
Modified nucleotides will possess a unique mass-to-charge ratio, and can easily be 
identified.  The absence of modified nucleotides would indicate the 5’-trfRNAGlu does 
not share its biogenesis with classic tRNAs. If some modified nucleotides are detected, 
combining mass spectrometry with sequence specific endonucleases can identify the 
location of the modifications. Fragmented trfRNAs can be compared to synthetic 
trfRNAs, and step-by-step, the exact chemical backbone of the 5’-trfRNAGlu can be 
deduced. Knowing the true chemical sequence of the 5’-trfRNAGlu will provide 
important details as to its origin. Furthermore, knowing the true chemical nature will be 
important for future studies aimed at identifying its function.  
How are sRNAs Transported into Synaptic Vesicles? 
The mechanism by which sRNAs are loaded into SVs and the location within the 
cell that SV loading occurs are not known. As discussed in previous section, sRNAs are 
products of nuclear transcription followed by cytosolic maturation and cleavage to 
mature miRNAs 160 or 5’-trfRNAs 148. Although not tested in this dissertation, at least 
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three pathways could lead to the loading of sRNAs into SVs for subsequent release into 
the synaptic cleft (Figure 20). In the first model, mature cytosolic sRNAs are loaded 
within the SVs during SV biogenesis and maturation, a process that also occurs within 
the neuronal cell body. Newly synthesized SVs would then be axonally transported to 
presynaptic terminals preloaded with sRNAs, and through activity driven fusion with the 
presynaptic membrane, lose their sRNAs in their initial fusion events (red). A second 
model for how sRNAs are loaded into SVs would be through an endocytotic event – 
either a clathrin mediated pathway in which sRNAs are captured by recycling SVs 
(yellow), or an endosomal mediated pathway in which sRNAs are uploaded into SVs 
during the SVs’ passage through endosomal recycling intermediates (green).  A third 
model resembles classic neurotransmitter loading. In this model mature sRNAs are 
loaded in SVs at nerve terminals. This model would require a protein or macromolecular 
complex, much like a neurotransmitter transporter, capable of loading SVs (blue).  Once 
released from the presynaptic terminal, sRNAs could be taken in by the postsynaptic 
cell. There, in association with the RISC complex, the sRNAs could affect local mRNA 
stability or translation. In an alternative model to the presynaptic release of sRNAs, 
endocytic SVs might engulf exogenous sRNAs. These sRNAs could be transported back 
to the presynaptic neuron cell body via retrograde transport (yellow).  
Although I did not test whether sRNAs are taken up by isolated SVs, I did detect 
by northern blot sRNAs and precursor sRNAs associated with isolated SVs. This finding 
suggests that some sRNAs might mature at the presynaptic terminal before being loaded 
into the lumen of the SVs. If so, there would need to be a mechanism to load sRNAs into  
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Figure 20. Potential pathways for sRNAs in the synapse. 
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SVs at the presynaptic terminals. One potential mechanism could be an undiscovered 
vesicular sRNA transporter. Although no such transporter is known, there are many SV 
proteins whose function remains unknown. Comparing the SV proteins to proteins 
capable of transporting RNA across membranes, such as the Systemic RNAi Defective 
(SID) family members161,162 might offer candidate vesicle transport proteins. 
Independent of identifying a molecular pathway, one could test whether sRNAs are 
actively loaded into isolated SVs. Much like radiolabeled neurotransmitters have been 
shown to load into isolated SVs, one could test whether radioactive synthetic sRNAs 
load into isolated SVs163. If so, is the process ATP dependent or independent? If it is 
ATP dependent, that would suggest an active transport pathway similar to that of classic 
neurotransmitters. 
Synaptic Vesicle sRNAs Co-effectors 
5’-trfRNAGlu has been shown to post-transcriptionally regulate protein synthesis 
via a siRNA and miRNA mechanism86. Whether 5’-trfRNAGlu regulates translation 
independently, or requires a co-effector, is not known. Many sRNAs do require co-
effectors. Proteins such as Argonaute (AGO) are known to bind RNAs, including 
microRNAs (miRNAs), short interfering RNAs (siRNAs) or PIWI-associated RNAs 
(piRNAs)164. AGO protein-RNA complexes can interact with other protein factors to 
coordinate downstream gene-silencing events164. In particular, AGO2 is known to bind 
microRNAs and further silence the target gene165. AGO2 bound RNA can either guide 
the target gene into a de-adenylation degradation pathway or form an active RNA-
induced silencing complex (RISC), which can induce endonucleolytic cleavage of 
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targeted mRNA165. Proteins that associate with sRNAs can be selectively isolated for 
further characterization166. One such approach is an RNA pull down assay. Briefly, high 
affinity tags are used to label a specific RNA. These tagged RNA molecules are then 
mixed with a cell or tissue extract. If a complex forms between the tagged RNA and a 
co-effector, the co-effector can then be isolated via the high affinity tag. The co-effector 
protein portion can be detected by western blotting or mass spectrometry167. To confirm 
a co-effector other techniques, including fluorescent in situ hybridization for RNA probe 
and immunohistochemistry to label the protein complex, may be required to further 
confirm the co-effector. If a new co-factor is discovered, it would add to the mechanisms 
available for post- transcriptional regulation of protein synthesis.  
Are SV sRNAs Specific for Different Neuronal Cell Types? 
Neurons are classified by the types of molecules, such as neurotransmitters they 
release at their synapses. One question that needs to be addressed is whether neurons can 
be classified by the types of SV sRNAs they release. Knowing the specific types of 
sRNAs released by specific neurons will be of great importance in understanding 
synaptic transmission at specific terminals. It will also be important knowledge because 
it will impact the study of sRNA uptake at the synapse, which I will briefly discuss in 
the next section. One way of studying the different species of sRNAs at specific neurons 
is to isolate synaptic vesicles using immunoprecipitation against different types of 
vesicular transporters. Once isolated, the SV sRNAs from different classes of neurons 
can be sequenced. Another proposed experiment would be to apply specific synthesized 
sRNAs to neuronal cell cultures in order to see if there is any post synaptic effect. For 
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example, would the application of cholinergic specific sRNAs to a neuronal cell culture, 
lead to changes in the types of post-synaptic receptors found in the culture? Ultimately, 
it will be important to catalog the types of sRNAs found within different types of 
neurons, including GABAergic, glutamatergic, serotonergic and dopaminergic neurons.  
sRNA Receptors and/or Cellular Uptake Mechanisms 
Protein translation occurs within cellular environments; therefore, if released SV 
sRNAs are to have an effect on post-synaptic targets, it is likely they must bind to a 
receptor for selective endocytosis or be taken into the target cells by a bulk mechanism. 
Potential postsynaptic cellular targets include neurons and /or glial cells, including 
oligodendricytes in the CNS, and muscles and/or Schwann Cells in the PNS. One 
potential class of receptors found on the plasma membrane of neurons and glial cells are 
the toll like receptor (TLR) families. Many classes of TLRs exist, and some can be 
activated by binding DNA or RNA168,169. In particular, TLR 7 and 8 can bind single 
stranded RNAs, and they have been localized to both the plasma membrane as well as 
endolysosomal compartments170. TLR 7 and 8 are expressed by neurons in the nervous 
system, including layer 9 motor neurons in the spinal cord (in situ hybridization, Allen 
Brain Atlas (© 2015 Allen Institute for Brain Science. Allen Brain Atlas [Internet]. 
Available from: http://www.brain-map.org.)). Immunohistochemistry with antibodies 
against TLR 7 and 8 could be used to test if these TLR receptors are found at neuronal 
synapses, and therefore potential candidate receptors for trfRNAs. For co-localization 
studies in cholinergic neurons, ACh receptor labels can be used136; while for co-
localization in Schwann Cells, glutamate receptors can be used171. To further support 
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this hypothesis, in situ hybridization on thin sections can be used as well. As further 
support for this hypothesis, in situ hybridization with sRNA antisense on thin sections 
can be used as well. If there is co - localization between sRNA antisense and TLR 7 or 8, 
it is possible they are the receptors for trfRNAs. Further tests would still be needed. 
Studies of neurons and glial cells of knock - out TLR 7 or 8 mice might shed further 
light on the pathway.   
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